

Donald R Mattison

Curriculum Vitae

EDUCATION:

M.D., College of Physicians and Surgeons, Columbia University, New York, NY, May, 1973.

M.S., Massachusetts Institute of Technology, Cambridge, MA, June, 1968.

Major: Chemistry.

Thesis: The Design and Construction of an 18 MHz Pulsed Nuclear Magnetic Resonance Spectrometer.

B.A. (Cum Laude), Augsburg College, Minneapolis, Minnesota

Majors: Chemistry and Mathematics, June, 1966.

CLINICAL TRAINING:

Obstetrics and Gynecology Residency, Sloane Hospital for Women, Columbia Presbyterian Medical Center, New York, New York: 1973 – 1975, 1977 – 1978.

Clinical Associate in Developmental and Reproductive Pharmacology and Toxicology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland: 1975 – 1977.

PROFESSIONAL CERTIFICATION:

Fellow, Academy of Toxicological Science, Recertified 2014.

Certified, General Toxicology, American Board of Toxicology, 1992.

APPOINTMENTS:

University of South Carolina Health Sciences Distinguished Professor: 2021—present.

Arnold School of Public Health, University of South Carolina, Columbia, South Carolina.

Chief Medical Officer and Senior Vice President: 2012 – present.

Risk Sciences International, Ottawa, Ontario, Canada and Hilton Head Island, South Carolina.

Associate Director: 2012 – present.

McLaughlin Centre for Population Health Risk Assessment
University of Ottawa

Adjunct Professor 2017 – present.

School of Epidemiology, Public Health and Preventive Medicine

University of Ottawa

Medical Advisor to *QuarterWatch: Monitoring FDA MedWatch Reports: 2013 – 2021.*

Institute for Safe Medication Practices, ISMP, Horsham PA.

Senior Research Fellow: 2014 – present

International Prevention Research Institute, iPRI, Lyon, France.

Senior Advisor to the Director of the *Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health: 2002 – 2012.*

**Chair, Federal Advisory Committee, National Children's Study,
Chief, Obstetric and Pediatric Pharmacology Branch CRMC and
Medical Officer, Epidemiology Branch, DESPR, NICHD, NIH.**

Medical Director, March of Dimes: 1998 – 2002.

March of Dimes Birth Defects Foundation

National Office, White Plains, New York.

Dean, Graduate School of Public Health, University of Pittsburgh: 1990 – 1998.

Professor of Environmental and Occupational Health
Graduate School of Public Health.

Professor of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine,
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh,
Pittsburgh, Pennsylvania.

Associate Professor to Professor, University of Arkansas for Medical Sciences: 1984 – 1990.

Department of Obstetrics and Gynecology and Pharmacology

University of Arkansas for Medical Sciences, Little Rock, AR.

Reserve Medical Officer, US Food and Drug Administration, USPHS: 1984 – 1990.

Director of the Human Risk Assessment Program

National Center for Toxicological Research, FDA, Jefferson, AR.

Medical Officer and Chief, Section on Reproductive Toxicology, NICHD, NIH: 1978 – 1984.

Pregnancy Research Branch, National Institute of Child Health and Human Development

National Institutes of Health

ACADEMIC BIOGRAPHICAL INFORMATION:

Scopus ID 7005724234

Researcher ID: <http://www.researcherid.com/rid/L-4661-2013>

ORCID ID 0000-0001-5623-0874

COMMUNITY SERVICE:

Director, Board of Directors and Chair of the Education Committee, Foundation for Advanced Education in the Sciences (FAES), National Institutes of Health, Bethesda MD: 2015 – 2020. The FAES provides education, social and cultural activities for staff, fellows and employees of the National Institutes of Health. The Board of directors provides oversight for FAES activities and the Education Committee provides oversight to the FAES Board and staff on education activity.

Mercy Health Clinic, Gaithersburg MD: 2003 – 2012. Volunteer physician and Associate Medical Director for a primary care community health clinic providing free outpatient medical care, pharmaceuticals and education to uninsured residents of the Montgomery County, MD community.

Volunteers in Medicine, Hilton Head Island, South Carolina: 2016 – Present. Volunteer physician and Chair of the Quality Improvement Committee for a multispecialty community health clinic providing free outpatient medical and surgical care, wellness, pharmaceuticals, and imaging for children and adults living in Hilton Head and Dufuskie Islands.

Trout Unlimited Conservation and Fly Fishing Camp: 2006 – 2012. (Tri-State region, Maryland/DC, Virginia and West Virginia) – Volunteer camp physician and member of the camp board.

MEDICAL LICENSES:

New York (121258, Active)

South Carolina (VL32359, Active)

Maryland (D0061516, Inactive)

Arkansas (N-67, Inactive)

Pennsylvania (MD-044789-L, Inactive)

Massachusetts (79113, Inactive)

UNIFORMED SERVICE:

U.S. Public Health Service, Captain (O6, Retired 2012)

USPHS Awards

Unit Commendation, Billet Transformation (January 2013)

Unit Commendation, Readiness (PHS May 2012)
Commissioned Corps Training Ribbon (PHS March 2007)
Outstanding Unit Citation (PHS January 2007)
Global Response Service Award (PHS October 2006)
Meritorious Unit Commendation (USN March 2007)
Hazardous Duty Award (PHS August 2006)
Foreign Duty Award (PHS August 2006)
Crisis Response Service Award (PHS January 2006)
Achievement Medal (PHS April 2005)
Crisis Response Service Award (PHS November 2004)

PHS Deployments and Training

2009 OFRD Medical Readiness Training, Fort A P Hill, Virginia
2009 IRCT Basic Online Course
2008 Rosebud Indian Health Service, South Dakota, clinical support in obstetrics and gynecology
2006 USNS MERCY Humanitarian Mission Philippines – Operation Enduring Freedom
2005 Hurricane Katrina
2005 Inauguration
2005 National Mall July 4th NPS Support
2004 Florida Hurricanes
2003 Anthrax Response
2003 Mass Vaccination with National Pharmaceutical Stockpile Course

USPHS Volunteer Activity

Associate Recruiter, PPAC Communications Committee, Readiness Working Group

EDITOR:

Manganese Showcase Symposium, Donald R Mattison, Len Levy, Doreen McGough, Editors, Special Issue of NeuroToxicology. 2017. <http://dx.doi.org/10.1016/j.neuro.2016.11.004>

Risk Science in the 21st Century, Tara Barton-Maclaren, Shalu Darshan, Donald R Mattison, Editors, Special Issue of the International Journal of Risk Assessment and Management. 2017, V20, 1/2/3.

<http://www.inderscience.com/info/inarticletoc.php?jcode=ijram&year=2017&vol=20&issue=1/2/3>

Computational Approaches for Reproductive and Developmental Toxicology, Donald R. Mattison, Editor, CRC Taylor and Francis Press, Published 2015. ISBN-13: 978-1439861073, ISBN-10: 1439861072

Clinical Pharmacology in Obstetrics, Donald R. Mattison, Editor, LWW Elsevier, Published December 2012. Academic Press ISBN: 9780123860071

Frontiers in Pediatric Clinical Pharmacology, Associate Editor for Perinatal Pharmacology, 2010 – 2012.

The Newborn Drug Development Initiative, George Giacoia, Debbie Birenbaum, Hari Sachs, Donald R. Mattison, Pediatrics Supplement Volume 117 March 2006.

The Role of Environmental Hazards in Premature Birth: Donald R. Mattison, Samuel Wilson, Christine Coussens, and Dalia Gilbert, *Editors*, Roundtable on Environmental Health Sciences, Research, and Medicine, National Academies Press, 2003

New Perspectives on the Stubborn Challenge of Preterm Birth, Pediatric and Prenatal Epidemiology, Volume 15, Supplement 2, July 2001.

EDITORIAL RESPONSIBILITY:

Waste Incineration and Public Health. Committee on Health Effects of Waste Incineration, National Research Council. National Academy Press, Washington, D.C., 1999.

Toward Environmental Justice: Research, Education and Health Policy Needs. Committee on Environmental Justice, Institute of Medicine. National Academy Press, Washington, D.C., 1999.

Government/Research Councils Initiative on Risk Assessment and Toxicology, Workshop on Strategies in Relation to Population Sub Groups. Institute for Environment and Health, April 1997.

International Program on Chemical Safety, Environmental Health Criteria 184: Diflubenzuron. World Health Organization, 1996.

International Program on Chemical Safety, Environmental Health Criteria 183: Chlorothalonil. World Health Organization, 1996.

International Program on Chemical Safety, Environmental Health Criteria 178: Methomyl. World Health Organization, 1996.

International Program on Chemical Safety, Environmental Health Criteria 177: 1, 2-Dibromoethane, World Health Organization, 1996.

CONSULTANT, PROFESSIONAL SERVICE AND ADMINISTRATIVE RESPONSIBILITY:

Society of Toxicology, Scientific Program Committee, 2012 – 2016.

American Society for Pharmacology and Experimental Therapeutics, Chair, Drug Discovery, Development and Regulatory Affairs Section, 2011 – 2015.

Canadian Institute for Health Research, IDCYH Advisory Board 2007 – 2012.

Japanese Ministry of Health, Consultation on Pediatric Clinical Trials Research, January 2007.

European Union, Directorate General for Research, Consultation on pediatric drug development, 2007 – 2010.

WHO Consultation, Pediatric Essential Medicines and Global research agenda for pediatric drug development, 2007 – 2009.

WHO Consultation, Global Burden of Foodborne Diseases, Geneva, September 2006.

WHO Consultation, Biomonitoring of Human Milk for Persistent Organic Pollutants, Geneva, September 2006.

WHO Consultation, Biomonitoring of Human Milk for Persistent Organic Pollutants, Geneva, June – July 2004.

Committee on the Evaluation of Children’s Health, Institute of Medicine, National Academy of Sciences. Chair: 2001 – 2002, Member 2002 – 2003.

Harvard Center for Risk Analysis Scientific Panel on Low-Dose Effects of Bisphenol A. Chair: 2001 – 2002.

Board of Scientific Counselors, Office of Research and Development, Environmental Protection Agency. Member: 2000 – 2003.

Collegiate Commission on Nursing Education. Board: 1999 – 2006; Treasurer: 2003 – 2006.

Science Advisory Board, US Environmental Protection Agency, Member, 1999- 2003.

Science Advisory Board, National Toxicology Program, National Institute of Environmental Health Sciences, NIH. Member: 1999 – 2004.

Science Advisory Board, Agency for Toxic Substances Disease Registry, Centers for Disease Control and Prevention. Member: 1999 – 2003.

Children’s Environmental Health Protection Advisory Committee, United States Environmental Protection Agency. Member: 1997 – 2003.

Commission on Life Sciences, National Research Council, National Academy of Sciences. Member: 1995 – 2000.

Committee on Environmental Justice, Board on Health Policy, Institute of Medicine. Member: 1995 – 1999.

Council for Education in Public Health. Representing the Association of Schools of Public Health. Counselor: 1995 – 1998.

Committee on Health Effects of Waste Incineration, Board on Environmental Studies and Toxicology, National Research Council. Chair and Member: 1994 – 2000.

Board on Environmental Studies and Toxicology, National Research Council. Member/Vice Chairman: 1987 – 1993/1997 – 2000.

Board of Directors, Pennsylvania Public Health Association. Member: 1993 – 1996.

Board on Health Promotion and Disease Prevention, Institute of Medicine, National Academy of Sciences. Member/Chairman: 1993 – 2000/1994 – 2000.

Scientific Advisory Board Hawaii Heptachlor Education and Research Foundation. Member/Chairman: 1987 – 2002/1999 – 2002.

MEMBER OF PROFESSIONAL ORGANIZATIONS:

American Association of Advancement of Science (1991-present)

American Society of Pharmacology and Experimental Therapeutics (2000-present)

Teratology Society (1990-present)

American Public Health Association (1990-present)

American College of Toxicology (1985-present)

Society for Gynecologic Investigation (1985-present)

Society of Toxicology (1985-present)

New York Academy of Science (1980-present)

New York Academy of Medicine (1980-present)

Drug Information Association (2010-present)

AWARDS AND HONORS:

Elected Foreign Fellow, Royal Society of Medicine, London, 2009

Distinguished Alumni, Augsburg College, 2005

Leveraging/Collaboration Award, Food and Drug Administration, 2005

Elected Member, National Academy of Medicine (previously Institute of Medicine), 2000

Elected Member, New York Academy of Medicine, 1999

Elected Fellow, American Association for the Advancement of Science, 1997

Elected Member, Delta Omega, Public Health Honor Society, 1991

FELLOWS, GRADUATE STUDENTS AND GUEST WORKERS:

Ms. Nisrine Haddad, 2015 – present, University of Ottawa

Ms. Nawal Farhat, 2014 – present, University of Ottawa

Mr. Yannick Fortin, 2012 – 2017, University of Ottawa

Mr. James Crispo, 2012 – 2016, University of Ottawa

Dr. Mohamed Taher, 2012 – present, University of Ottawa

Dr. Chris Gravel, 2012 – 2017, University of Ottawa, McGill University and Carleton University

Ms. Melissa Davidson, 2012 – present, University of Ottawa

Mr. Tim Prendergast, 2012 – 2014, University of Ottawa and Carleton University

Ms. Lan Zhuo, 2012, University of Ottawa

Dr. Sophie Hamel, 2012 – 2015, University of Ottawa

Ms. Amanda Filiberto, 2011-2012, Epidemiology Branch, NICHD

Ms. Hali Hambridge, 2011-2012, Johns Hopkins School of Public Health

Ms. Sonya Dasharathy, 2010-2011, New York University Medical School

Mr. Sergio Espada, 2010, Pennsylvania State University, deceased.

Dr. Maisa Feghali, 2009 – 2011, Obstetrics and Gynecology Resident Georgetown University

Dr. Offie Soldin, 2005 – 2011, Departments of Obstetrics and Gynecology, Physiology and Pharmacology, Georgetown University, deceased.

Ms. Jeannette Gómez, 1992-1998. Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA.

Ms. Debra Lee Stark, 1992-1993. Department of Health Services Administration, University of Pittsburgh, Pittsburgh, PA

Dr. C.V. Damaraju 1992-1993. Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA.

Dr. Antoine Malek, 1988-1990, 2008 – 2013. Department of Obstetrics and Gynecology, University of Berne, Berne, Switzerland.

Dr. Barbara Vogt, 1986-1993. Division of Interdisciplinary Toxicology, Department of Pharmacology, University of Arkansas for Medical Sciences, Little Rock, AR.

Dr. David Plowchalk, 1986-1993. Division of Interdisciplinary Toxicology, Department of Pharmacology, University of Arkansas for Medical Sciences, Little Rock, AR.

GRADUATE THESIS SUPERVISED:

Yannick Fortin, Role of Comorbidities in Motor Vehicle Accidents. Faculty of Health Sciences, University of Ottawa, Ottawa, Canada. PhD 2017.

James A.G. Crispo, Pharmacotherapies in Parkinson Disease: Investigating Trends and Adverse Health Outcomes. Faculty of Health Sciences, University of Ottawa, Ottawa Ontario, Canada, Ph.D., 2016.

Sophie Hamel.

Cardiovascular effects and pattern of use of antineoplastic therapies in female breast cancer patients. Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada, Ph.D., 2014.

Jeannette Gómez, Rule-Learner: An Alternative Method to Evaluate Potential Human Developmental Toxicants. Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, M.S., 1996.

Barbara Vogt, Biomarkers of Alcohol Consumption. Department of Pharmacology and Interdisciplinary Toxicology. University of Arkansas for Medical Sciences and American Health Foundation, Valhalla, NY, Ph.D., 1994.

Mark Zorbas, Immunological and Pharmacokinetic Studies of Arylcyclohexylamine Receptor and Covalent Binding. Department of Pharmacology, University of Arkansas for Medical Sciences, Ph.D., 1990.

David Plowchalk, Cyclophosphamide Ovarian Toxicity. Department of Pharmacology and Interdisciplinary Toxicology, University of Arkansas for Medical Sciences, Ph.D., 1989.

Denise Nelson, Phenytoin Plasma Protein Binding In Diabetic Mothers and Their Infants. College of Pharmacy, University of Arkansas for Medical Sciences, M.S., 1987

Sanford Bigelow, Genetic Studies Concerning the Induction of Aryl Hydrocarbon Hydroxylase Governed by the Murine Ah Locus. Department of Chemistry, American University, Ph.D., 1985.

William Dawe, Human Placental Transport: In-Vitro. Department of Biology, American University, M.S, 1983.

Haydeh Payami, Ovarian Mediated Mutagenesis. Department of Biology, American University, M.S, 1981.

GRADUATE COURSES ORGANIZED AND TAUGHT:

Risk Based Decision-Making. Course organized and taught by members and affiliates of Risk Sciences International during 2015, 2016, 2017 in Ottawa, ON.

Pharmacovigilance Working Group Research Seminar, McLaughlin Centre for Population Health Risk Assessment. Research seminar co-organized with Dan Krewski during the 2012-2013, 2013-2014, 2014-2015, 2015-2016 academic years at the University of Ottawa for approximately 30 participants (graduate students, fellows, and faculty).

Pharmacovigilance Seminar, South Carolina College of Pharmacy. Seminar course organized and taught during the 2012-2013 academic year at the invitation and sponsorship of the Provost of the University of South Carolina for approximately 30 students.

Summer Institute in Obstetric and Pediatric Pharmacology This was a unique course developed and implemented in collaboration with the National Institutes of Health (NIH), and the Canadian Institute for Health Research (CIHR) and was presented annually with CIHR funding from 2005 through 2015 to approximately 20 US, Canadian and international students each year.

European Course on the Evaluation of Medicinal Products in Children, University of Paris Descartes, University Claude Bernard Lyon, European Society for Developmental Perinatal and Pediatric Pharmacology. Course developed and taught annually from 2002- 2013 to approximately 50 international students each year. Successful completion of the course leads to a certificate.

Overview of Endocrine, Reproductive and Developmental Toxicology, Department of Environmental Health, Mailman School of Public Health, Columbia University (this is a single 3 hour survey lecture as part of the core course on toxicology taught each spring from 2002 to 2008)

Introduction to Endocrine, Reproductive and Developmental Toxicology, Department of Environmental Health, Mailman School of Public Health, Columbia University (Spring Term 2002, 10 students; Summer 2003, 15 students)

Introduction to Risk Analysis (EOH 2180), Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh (Summer 1992, 7 students; Summer 1993, 13 students; Summer 1994, 23 students; Summer 1995, 16 students; Summer 1997, 10 students).

Risk Assessment Practicum (EOH 2181), Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh (Summer 1994, 13 students; Summer 1995, 10 students; Summer 1997, 5 students).

Politics of Public Health in Pennsylvania (PUBHLT 2003), Department of Health Services Administration, Graduate School of Public Health, University of Pittsburgh (Fall 1994, 4 students; Fall 1996, 3 students).

Federal Politics of Public Health (HSADM2205), Department of Health Services Administration, Graduate School of Public Health, University of Pittsburgh (Spring 1995, 2 students).

An Integrative Course on Violence (PUBHLT 2001), Graduate School of Public Health, University of Pittsburgh (Spring 1996, 3 students; Spring 1997, 7 students).

Publications

NCBI Bibliography:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/donald.mattison.1/bibliography/9271547/public/?sort=date&direction=descending>

Mattison 19Jan2020v1 Bibliography

1. Loukotkova L, Basavarajappa M, Lumen A, Roberts R, Mattison D, Morris SM, Fisher J, Beland FA, Gamboa da Costa G. Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys. *Regul Toxicol Pharmacol.* 2020;104569. Epub 2020/01/14. doi: 10.1016/j.yrtph.2019.104569. PubMed PMID: 31927005.
2. Kadry Taher M, Farhat N, Karyakina NA, Shilnikova N, Ramoju S, Gravel CA, Krishnan K, Mattison D, Wen SW, Krewski D. Critical review of the association between perineal use of talc powder and risk of ovarian cancer. *Reprod Toxicol.* 2019;90:88-101. Epub 2019/09/01. doi: 10.1016/j.reprotox.2019.08.015. PubMed PMID: 31472245.
3. Farhat N, Haddad N, Crispo J, Birkett N, McNair D, Momoli F, Wen SW, Mattison DR, Krewski D. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016. *Eur J Clin Pharmacol.* 2019;75(2):227-35. Epub 2018/10/17. doi: 10.1007/s00228-018-2564-8. PubMed PMID: 30324301.
4. Farhat N, Fortin Y, Haddad N, Birkett N, Mattison DR, Momoli F, Wu Wen S, Krewski D. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. *Crit Rev Toxicol.* 2019;49(3):215-61. Epub 2019/06/14. doi: 10.1080/10408444.2019.1583167. PubMed PMID: 31192763.
5. Moore TJ, Mattison DR. Assessment of Patterns of Potentially Unsafe Use of Zolpidem. *JAMA internal medicine.* 2018. Epub 2018/07/18. doi: 10.1001/jamainternmed.2018.3031. PubMed PMID: 30014137.
6. Farhat N, Haddad N, Crispo J, Birkett N, McNair D, Momoli F, Wen S-W, Mattison D, Krewski D. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016. *Eur J Clin Pharmacol.* 2018;in Press.
7. Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. *Crit Rev Toxicol.* 2018;48(1):52-108. Epub 2017/08/18. doi: 10.1080/10408444.2017.1351420. PubMed PMID: 28816105.
8. Bjerre LM, Parlow S, de Launay D, Hogel M, Black CD, Mattison DR, Grimshaw JM, Watson MC. Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK. *BMJ Open.* 2018;8(10):e020150. Epub 2018/10/10. doi: 10.1136/bmjopen-2017-020150. PubMed PMID: 30297342; PMCID: PMC6194396.
9. Yannick F, Crispo JAG, Cohen D, Dahrouge S, McNair D, Mattison D, Krewski D. An exposure-response relationship between multimorbidity and motor-vehicle accidents. *Journal of Transport & Health.* 2017;4:140-51.
10. Ramoju SP, Mattison DR, Milton B, McGough D, Shilnikova N, Clewell HJ, Yoon M, Taylor MD, Krewski D, Andersen ME. The application of PBPK models in estimating human brain tissue manganese concentrations. *Neurotoxicology.* 2017;58:226-37. doi: 10.1016/j.neuro.2016.12.001. PubMed PMID: 27989617.
11. Moore TJ, Mattison DR. Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. *JAMA internal medicine.* 2017;177(2):274-5. doi: 10.1001/jamainternmed.2016.7507. PubMed PMID: 27942726.

12. Moore TJ, Furberg CD, Mattison DR, Cohen MR. Perspective from New Adverse Event Reports: Antidepressants. New Data from 2016 Quarter2. QuarterWatch Monitoring FDA MedWatch Reports [Internet]. 2017 January 25, 2017. Available from: www.ismp.org/QuarterWatch/.
13. Milton B, Krewski D, Mattison DR, Karyakina NA, Ramoju S, Shilnikova N, Birkett N, Farrell PJ, McGough D. Modeling U-shaped dose-response curves for manganese using categorical regression. *Neurotoxicology*. 2017;58:217-25. doi: 10.1016/j.neuro.2016.10.001. PubMed PMID: 27720796.
14. Mattison DR, Milton B, Krewski D, Levy L, Dorman DC, Aggett PJ, Roels HA, Andersen ME, Karyakina NA, Shilnikova N, Ramoju S, McGough D. Severity scoring of manganese health effects for categorical regression. *Neurotoxicology*. 2017;58:203-16. doi: 10.1016/j.neuro.2016.09.001. PubMed PMID: 27637608.
15. Mattison DR, Levy L, McGough D. Manganese showcase symposium. *Neurotoxicology*. 2017;58:171-2. doi: 10.1016/j.neuro.2016.11.004. PubMed PMID: 27880872.
16. Mattison DR. PK/PD Modelling for Multiple Exposures in Pregnancy. *Birth Defects Research*. 2017;109(9):631-. PubMed PMID: WOS:000401275300017.
17. Gurusankar R, Yenugadhati N, Krishnan K, Hays SM, Haines D, Zidek A, Kuchta S, Kinniburgh D, Gabos S, Mattison DR, Krewski D. The Role of Human Biological Monitoring (HBM) in Health Risk Assessment. *International Journal of Risk Assessment and Management*. 2017;20(1/2/3).
18. Fortin Y, Crispo JAG, Cohen D, McNair DS, Mattison DR, Krewski D. External validation and comparison of two variants of the Elixhauser comorbidity measures for all-cause mortality. *PloS one*. 2017;12(3). doi: 10.1371/journal.pone.0174379. PubMed PMID: WOS:000399174400030.
19. Fortin Y, Crispo JAG, Cohen D, Dahrouge S, McNair DS, Mattison DR, Krewski D. An exposure-response relationship between multimorbidity and motor-vehicle accidents. *Journal of Transport & Health*. 2017;4:140-51. doi: 10.1016/j.jth.2017.01.006. PubMed PMID: WOS:000403125400017.
20. Fortin Y, Crispo JA, Cohen D, McNair D, Mattison DR, Krewski D. Optimal Look Back Period and Summary Method for Elixhauser Comorbidity Measures in a U.S. Population-Based Electronic Health Record Database. *Open Access Medical Statistics* 2017;7:1-13.
21. Barton-MacLaren TS, Westphal M, Sarwar E, Mattison DR, Chiu W, Dix D, Kavlock R, Krewski D. Challenges and Opportunities in the Risk Assessment of Existing Substances in Canada: Lessons Learned from the International Community. *International Journal of Risk Assessment and Management* 2017;20(1/2/3).
22. Barton-MacLaren TS, Darshan S, Mattison DR. Risk Science in the 21st Century. *International Journal of Risk Assessment and Management* 2017;20(1/2/3).
23. Abu Alhassin M, Krewski D, Mattison DR. EVALUATION OF EFFECTIVENESS OF HEALTH CANADA'S DEAR HEALTHCARE PROFESSIONAL LETTERS ON PRESCRIBING PRACTICE IN CANADA. *Value in Health*. 2017;20(5):A64-A. PubMed PMID: WOS:000405448000335.
24. Sharma S, Caritis S, Hankins G, Miodovnik M, Hebert MF, Mattison D, Venkataramanan R. Population pharmacokinetics of 17alpha-hydroxyprogesterone caproate in singleton gestation. *Br J Clin Pharmacol*. 2016;82(4):1084-93. doi: 10.1111/bcp.12990. PubMed PMID: 27133963; PMCID: PMC5137834.
25. Moore TJ, Furberg CD, Mattison DR, Cohen MR. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. *Pharmacoepidemiol Drug Saf*. 2016;25(6):713-8. doi: 10.1002/pds.3979. PubMed PMID: 26861066.
26. Moore TJ, Furberg CD, Mattison DR, Cohen MR. Problems with a patch and a self-injection pen. QuarterWatch Monitoring FDA MedWatch Reports [Internet]. 2016 October 5, 2016.
27. Moore TJ, Furberg CD, Mattison DR, Cohen MR. QuarterWatch 2015 Quarter 4: Annual Report Issue. QuarterWatch [Internet]. 2016. Available from: <http://www.ismp.org/QuarterWatch/pdfs/2014Q4.pdf> .

28. Moore TJ, Furberg CD, Mattison DR, Cohen MR. QuarterWatch: Safety Perspectives Data from 2015 Quarter 3. QuarterWatch: Monitoring FDA MedWatch Reports [Internet]. 2016 2015 Quarter 3:[1-14 pp.]. Available from: www.ismp.org/QuarterWatch/.
29. Mattison DR. Computational methods for reproductive and developmental toxicology. Boca Raton: CRC Press, Taylor & Francis Group; 2016. xiv, 327 pages p.
30. Koren G, Hankins GD, Clark S, Caritis SN, Miodovnik M, Umans JG, Mattison DR. Effectiveness of doxylamine-pyridoxine for morning sickness. *Am J Obstet Gynecol*. 2016;214(5):664-6. doi: 10.1016/j.ajog.2016.01.186. PubMed PMID: 26844757.
31. Koren G, Clark S, Hankins GD, Caritis SN, Umans JG, Miodovnik M, Mattison DR, Matok I. Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy. *BMC pregnancy and childbirth*. 2016;16(1):371. doi: 10.1186/s12884-016-1172-9. PubMed PMID: 27881103; PMCID: PMC5122025.
32. Johnson KA, Sjaarda LA, Mumford SL, Garbose RA, Schliep KC, Mattison D, Perkins NJ, Wactawski-Wende J, Schisterman EF. Patterns and prevalence of medication use across the menstrual cycle among healthy, reproductive aged women. *Pharmacoepidemiol Drug Saf*. 2016;25(6):618-27. doi: 10.1002/pds.3993. PubMed PMID: 26954695; PMCID: PMC4933290.
33. Hamel S, McNair DS, Birkett NJ, Mattison DR, Krantis A, Krewski D. Cardiovascular risks associated with estrogen-targeted therapy in post-menopausal women with breast cancer. In Review. 2016;In Review.
34. Fortin Y, Crispo JA, McNair DS, Cohen D, Dahrouge S, Mattison DR, Krewski D. RISK OF MOTOR-VEHICLE ACCIDENTS INCREASES WITH MULTIMORBIDITY. *Value in Health*. 2016;19(7):A630-A. doi: 10.1016/j.jval.2016.09.1631. PubMed PMID: WOS:000396606301725.
35. Farhat N, Fortin Y, Birkett N, Mattison DR, Krewski D. PROTON PUMP INHIBITORS AND MAJOR ADVERSE CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW. *Value in Health*. 2016;19(7):A640-A. doi: 10.1016/j.jval.2016.09.1692. PubMed PMID: WOS:000396606301781.
36. Crispo JAG, Willis AW, Thibault DP, Fortin Y, Hays HD, McNair DS, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison DR, Krewski D. Associations Between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease. *Pharmacoepidemiology and Drug Safety*. 2016;25:451-2. PubMed PMID: WOS:000385483503042.
37. Crispo JAG, Willis AW, Thibault DP, Fortin Y, Emons M, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison D, Krewski D. Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease. *Movement Disorders Clinical Practice*. 2016;3(3):257-67. doi: 10.1002/mdc3.12286. PubMed PMID: WOS:000383248600005.
38. Crispo JA, Willis AW, Thibault DP, Fortin Y, Hays HD, McNair DS, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison DR, Krewski D. Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease. *PloS one*. 2016;11(3):e0150621. doi: 10.1371/journal.pone.0150621. PubMed PMID: 26939130; PMCID: PMC4777375.
39. Crispo J, Willis A, Thibault D, Fortin Y, Hays H, McNair D, Bjerre L, Kohen D, Perez-Lloret S, Mattison D, Krewski D. Associations Between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease. *Neurology*. 2016;86. PubMed PMID: WOS:000411328600014.
40. Tully I, Draper ES, Lamming CR, Mattison D, Thomas C, Martland T, Appleton R. Admissions to paediatric intensive care units (PICU) with refractory convulsive status epilepticus (RCSE): A two-year multi-centre study. *Seizure-European Journal of Epilepsy*. 2015;29:153-61. doi: 10.1016/j.seizure.2015.04.002. PubMed PMID: WOS:000357767800025.
41. Moore TJ, Furberg CD, Mattison DR, Cohen MR. QuarterWatch 2014 Quarters 3-4. Annual Report Issue. QuarterWatch Monitoring FDA MedWatch Reports [Internet]. 2015 September 23, 2015. Available from: www.ismp.org/QuarterWatch.

42. Moore TJ, Furberg CD, Mattison DR, Cohen MR. QuarterWatch 2014 Quarter 2: Zolpidem, Canagliflozin, Rosiglitazone. QuarterWatch, Monitoring FDA MedWatch Reports [Internet]. 2015 May 6, 2015. Available from: www.ismp.org/QuarterWatch/.
43. Moore TJ, Cohen MR, Furberg CD, Mattison DR. QuarterWatch 2013 Quarter 4, 2014 Quarter 1: A Critique of a Key Drug Safety Reporting System. QuarterWatch, Monitoring FDA MedWatch Reports [Internet]. 2015 January 28, 2015. Available from: www.ismp.org/QuarterWatch/.
44. Matyas RA, Mumford SL, Schliep KC, Ahrens KA, Sjaarda LA, Perkins NJ, Filiberto AC, Mattison D, Zarek SM, Wactawski-Wende J, Schisterman EF. Effects of over-the-counter analgesic use on reproductive hormones and ovulation in healthy, premenopausal women. *Hum Reprod*. 2015;30(7):1714-23. doi: 10.1093/humrep/dev099. PubMed PMID: 25954035; PMCID: PMC4472321.
45. LaKind JS, Goodman M, Makris SL, Mattison DR. Improving Concordance in Environmental Epidemiology: A Three-Part Proposal. *Journal of toxicology and environmental health Part B, Critical reviews*. 2015;18(2):105-20. doi: 10.1080/10937404.2015.1051612. PubMed PMID: 26158301; PMCID: PMC4733943.
46. Koren G, Clark S, Hankins GD, Caritis SN, Umans JG, Miodovnik M, Mattison DR, Matok I. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. *BMC pregnancy and childbirth*. 2015;15:59. doi: 10.1186/s12884-015-0488-1. PubMed PMID: 25884778; PMCID: PMC4391332.
47. Hamel S, McNair DS, Birkett NJ, Mattison DR, Krantis A, Krewski D. Off-label use of cancer therapies in women diagnosed with breast cancer in the United States. *Springerplus*. 2015;4:209. doi: 10.1186/s40064-015-0981-z. PubMed PMID: 25977897; PMCID: PMC4422830.
48. Fortin Y, Crispo J, Emons MF, Mattison DR, Krewski D. COMPARING THE PREDICTIVE PERFORMANCE OF TWO VARIANTS OF THE ELIXHAUSER COMORBIDITY MEASURES FOR ALL-CAUSE IN-HOSPITAL MORTALITY IN A LARGE MULTI-PAYER US ADMINISTRATIVE DATABASE. *Value in Health*. 2015;18(3):A13-A. doi: 10.1016/j.jval.2015.03.086. PubMed PMID: WOS:000354498500064.
49. Crispo JAG, Fortin Y, Sikora L, Kohen DE, Bjerre LM, Mattison DR, Perez-Lloret S, Hessian RC, Willis AW, Krewski D, Crispo JAG. Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease. *Cochrane Database of Systematic Reviews*. 2015(8). doi: 10.1002/14651858.cd011843.
50. Crispo JAG, Fortin Y, Emons M, Bjerre LM, Kohen DE, Lloret SP, Mattison DR, Willis AW, Krewski D. AntiParkinson's drug use in response to practice parameter publication, drug availability, and 'unofficial' prescribing forces. *Movement Disorders*. 2015;30:S77-S. PubMed PMID: WOS:000356598200199.
51. Crispo JA, Fortin Y, Thibault DP, Emons M, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison D, Willis AW, Krewski D. Trends in inpatient antiparkinson drug use in the USA, 2001-2012. *Eur J Clin Pharmacol*. 2015;71(8):1011-9. doi: 10.1007/s00228-015-1881-4. PubMed PMID: 26081062; PMCID: PMC4500853.
52. Crispo J, Willis AW, Fortin Y, Emons MF, Bjerre LM, Kohen DE, Lloret SP, Mattison DR, Krewski D. RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH NECESSARY INTERVENTIONS FOR PARKINSON DISEASE. *Value in Health*. 2015;18(3):A278-A. doi: 10.1016/j.jval.2015.03.1624. PubMed PMID: WOS:000354498504294.
53. Yang X, Morris SM, Gearhart JM, Ruark CD, Paule MG, Slikker W, Jr., Mattison DR, Vitiello B, Twaddle NC, Doerge DR, Young JF, Fisher JW. Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. *PloS one*. 2014;9(9):e106101. doi: 10.1371/journal.pone.0106101. PubMed PMID: 25184666; PMCID: PMC4153582.

54. Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. *Eur J Obstet Gynecol Reprod Biol.* 2014;175:124-8. doi: 10.1016/j.ejogrb.2014.01.019. PubMed PMID: 24502872.
55. Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. *BJOG : an international journal of obstetrics and gynaecology.* 2014;121(9):1090-6. doi: 10.1111/1471-0528.12678. PubMed PMID: 24628701.
56. Williams D, Basavarajappa MS, Rasmussen SA, Morris S, Mattison D, Animal Models of Pregnancy Working G. Highlights from the United States Food and Drug Administration's public workshop on the development of animal models of pregnancy to address medical countermeasures in an "at-risk" population of pregnant women: Influenza as a case study. *Birth defects research Part A, Clinical and molecular teratology.* 2014;100(10):806-10. doi: 10.1002/bdra.23319. PubMed PMID: 25296888.
57. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. *JAMA internal medicine.* 2014;174(12):1930-3. doi: 10.1001/jamainternmed.2014.5262. PubMed PMID: 25329919.
58. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. *Bmj.* 2014;349:g4517. doi: 10.1136/bmj.g4517. PubMed PMID: 25056265.
59. Moore TJ, Cohen MR, Furberg CD, Mattison DR. QuarterWatch 2013 Quarter 1: Perspective on Drug Hypersensitivity. *QuarterWatch, Monitoring FDA MedWatch Reports [Internet].* 2014 May 7, 2014. Available from: www.ismp.org/QuarterWatch/.
60. Moore TJ, Cohen MR, Furberg CD, Mattison DR. QuarterWatch: Adverse Drug Events in Children Under Age 18. *QuarterWatch, Monitoring FDA MedWatch Reports [Internet].* 2014 January 16, 2014. Available from: www.ismp.org/QuarterWatch/.
61. Moore TJ, Cohen MR, Furberg CD, Mattison DR. QuarterWatch 2013 Quarters 2 & 3: Dimethyl Fumarate, Varenicline, Sodium Oxybate, Fingolimod. *QuarterWatch, Monitoring FDA MedWatch Reports [Internet].* 2014 September 24, 2014. Available from: www.ismp.org/QuarterWatch/.
62. Mattison DR, Karyakina N, Goodman M, LaKind JS. Pharmacokinetics and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps. *Crit Rev Toxicol.* 2014;44(8):696-724. doi: 10.3109/10408444.2014.930813. PubMed PMID: 25099693.
63. Mattison DR. In Utero Vulnerability and Gamete Development. *Environmental and Molecular Mutagenesis.* 2014;55:S18-S. PubMed PMID: WOS:000341176900006.
64. Matok I, Clark S, Caritis S, Miodovnik M, Umans JG, Hankins G, Mattison DR, Koren G. Studying the antiemetic effect of vitamin B6 for morning sickness: pyridoxine and pyridoxal are prodrugs. *Journal of clinical pharmacology.* 2014;54(12):1429-33. doi: 10.1002/jcph.369. PubMed PMID: 25052410.
65. Lakind JS, Goodman M, Mattison DR. Bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: a systematic review of epidemiologic research. *Crit Rev Toxicol.* 2014;44(2):121-50. doi: 10.3109/10408444.2013.860075. PubMed PMID: 24392816.
66. Goodman M, Lakind JS, Mattison DR. Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature. *Crit Rev Toxicol.* 2014;44(2):151-75. doi: 10.3109/10408444.2013.860076. PubMed PMID: 24417397.
67. Goodman M, LaKind JS, Fagliano JA, Lash TL, Wiemels JL, Winn DM, Patel C, Van Eenwyk J, Kohler BA, Schisterman EF, Albert P, Mattison DR. Cancer cluster investigations: review of the past and proposals for the future. *Int J Environ Res Public Health.* 2014;11(2):1479-99. doi: 10.3390/ijerph110201479. PubMed PMID: 24477211; PMCID: PMC3945549.
68. Crispo J, Fortin Y, Sikora L, Lloret SP, Mattison D, Krewski D. Risk of adverse cardiovascular reactions in Parkinson's disease patients treated with pramipexole: A systematic review. *Movement Disorders.* 2014;29:S541-S2. PubMed PMID: WOS:000337693403364.

69. Aylward LL, Hays SM, Kirman CR, Marchitti SA, Kenneke JF, English C, Mattison DR, Becker RA. Relationships of chemical concentrations in maternal and cord blood: a review of available data. *Journal of toxicology and environmental health Part B, Critical reviews*. 2014;17(3):175-203. doi: 10.1080/10937404.2014.884956. PubMed PMID: 24749481.
70. Xie RH, Guo Y, Krewski D, Mattison D, Nerenberg K, Walker MC, Wen SW. Trends in using beta-blockers and methyl dopa for hypertensive disorders during pregnancy in a Canadian population. *Eur J Obstet Gynecol Reprod Biol*. 2013;171(2):281-5. doi: 10.1016/j.ejogrb.2013.09.032. PubMed PMID: 24139131.
71. Sharma S, Ellis EC, Gramignoli R, Dorko K, Tahan V, Hansel M, Mattison DR, Caritis SN, Hines RN, Venkataramanan R, Strom SC. Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes. *Drug Metab Dispos*. 2013;41(2):296-304. doi: 10.1124/dmd.112.044891. PubMed PMID: 23129211; PMCID: PMC3558857.
72. Reed MD, Mattison DR. Treating the Placenta: an Evolving Therapeutic Concept. In: Mattison DR, editor. *Clinical Pharmacology During Pregnancy*. 1st edn. ed. Amsterdam: Academic Press; 2013. p. 73-87.
73. Pollack AZ, Mumford SL, Wactawski-Wende J, Yeung E, Mendola P, Mattison DR, Schisterman EF. Bone mineral density and blood metals in premenopausal women. *Environ Res*. 2013;120:76-81. doi: 10.1016/j.envres.2012.06.001. PubMed PMID: 23122770; PMCID: PMC3534953.
74. Mumford SL, Dasharathy SS, Pollack AZ, Perkins NJ, Mattison DR, Cole SR, Wactawski-Wende J, Schisterman EF. Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. *Hum Reprod*. 2013;28(7):1853-62. doi: 10.1093/humrep/det085. PubMed PMID: 23562957; PMCID: PMC3685334.
75. Moore TJ, Cohen MR, Furberg CD, Mattison DR. QuarterWatch 2012 Quarter 4: Leading Drug Safety Issues of 2012. *QuarterWatch, Monitoring FDA MedWatch Reports [Internet]*. 2013 October 17, 2013. Available from: www.ismp.org/QuarterWatch/.
76. Mattison DR. *Clinical pharmacology during pregnancy*. 1st ed. London ; Waltham, MA: Academic Press; 2013. xxi, 471 p. p.
77. Mattison DR. Pharmacokinetics in real life: Sex and gender differences. *Journal of Population Therapeutics and Clinical Pharmacology*. 2013;20(3):e340-e9. PubMed PMID: 1461700058; 2013709775.
78. Mattison DR. Introduction. In: Mattison DR, editor. *Clinical Pharmacology During Pregnancy*. Amsterdam: Academic Press; 2013. p. 1-4.
79. Matok I, Umans J, Feghali MN, Clark S, Caritis S, Miodovnik M, Hankins G, Mattison DR, Nordeng H, Koren G. Characteristics of women with nausea and vomiting of pregnancy who chose to continue compassionate use of placebo after a randomised trial. *Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology*. 2013;33(6):557-60. doi: 10.3109/01443615.2013.774327. PubMed PMID: 23919849.
80. Kalpatthi R, Thompson B, Lu M, Wang WC, Patel N, Kutlar A, Howard T, Luchtman-Jones L, Miller ST, Investigators BH. Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. *Clin Biochem*. 2013;46(3):278-81. doi: 10.1016/j.clinbiochem.2012.10.032. PubMed PMID: 23123915; PMCID: PMC4550480.
81. Hambridge HL, Mumford SL, Mattison DR, Ye A, Pollack AZ, Bloom MS, Mendola P, Lynch KL, Wactawski-Wende J, Schisterman EF. The influence of sporadic anovulation on hormone levels in ovulatory cycles. *Hum Reprod*. 2013;28(6):1687-94. doi: 10.1093/humrep/det090. PubMed PMID: 23589536; PMCID: PMC3657125.
82. van Hasselt JG, Andrew MA, Hebert MF, Tarning J, Vicini P, Mattison DR. The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics. *Br J Clin Pharmacol*. 2012;74(6):932-9. doi: 10.1111/j.1365-2125.2012.04280.x. PubMed PMID: 22452385; PMCID: PMC3522806.

83. Valluri S, Zito JM, Pao M, Ballard ED, Safer DJ, Korelitz JJ, Mattison DR, Wayne AS. Antidepressant treatment of Medicaid-insured youth with a cancer diagnosis. *Journal of Pharmaceutical Health Services Research*. 2012;3(2):109-14. doi: 10.1111/j.1759-8893.2011.00069.x.
84. Mumford SL, Steiner AZ, Pollack AZ, Perkins NJ, Filiberto AC, Albert PS, Mattison DR, Wactawski-Wende J, Schisterman EF. The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. *The Journal of clinical endocrinology and metabolism*. 2012;97(10):E1871-9. doi: 10.1210/jc.2012-1350. PubMed PMID: 22837188; PMCID: PMC3674299.
85. Morris SM, Petibone DM, Lin WJ, Chen JJ, Vitiello B, Witt KL, Mattison DR. The genetic toxicity of methylphenidate: a review of the current literature. *J Appl Toxicol*. 2012;32(10):756-64. Epub 2012/02/18. doi: 10.1002/jat.2721. PubMed PMID: 22337063.
86. Mattison Faye A, Mattison D. Drug Disposition and Effect. In: Schenck-Gustafsson K, DeCola P, Pfaff D, DS P, editors. *Handbook of clinical gender medicine*. Basel: Karger; 2012. p. 473-9.
87. Dasharathy SS, Mumford SL, Pollack AZ, Perkins NJ, Mattison DR, Wactawski-Wende J, Schisterman EF. Menstrual bleeding patterns among regularly menstruating women. *Am J Epidemiol*. 2012;175(6):536-45. doi: 10.1093/aje/kwr356. PubMed PMID: 22350580; PMCID: PMC3299419.
88. Chetty M, Mattison D, Rostami-Hodjegan A. Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. *Curr Drug Metab*. 2012;13(6):778-86. PubMed PMID: 22452452.
89. Chen B, Restaino J, Norris L, Xirasagar S, Qureshi ZP, McKoy JM, Lopez IS, Trener A, Murday A, Kahn A, Mattison DR, Ray P, Sartor O, Bennett CL. A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. *Journal of oncology practice / American Society of Clinical Oncology*. 2012;8(6):e158-67. doi: 10.1200/JOP.2011.000504. PubMed PMID: 23598851; PMCID: PMC3500490.
90. Caritis SN, Sharma S, Venkataramanan R, Hankins GD, Miodovnik M, Hebert MF, Umans JG, Benedetti T, Mattison D, Zajicek A, Fischer D, Jackson A, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetrical-Fetal Pharmacology Research Units N. Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. *Am J Obstet Gynecol*. 2012;207(5):398 e1-8. doi: 10.1016/j.ajog.2012.08.015. PubMed PMID: 22967833; PMCID: PMC3586341.
91. Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trener A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). *J Gen Intern Med*. 2012;27(12):1697-703. doi: 10.1007/s11606-012-2098-1. PubMed PMID: 22692632; PMCID: PMC3509314.
92. Youngstrom E, Kenworthy L, Lipkin PH, Goodman M, Squibb K, Mattison DR, Anthony LG, Makris SL, Bale AS, Raffaele KC, LaKind JS. A proposal to facilitate weight-of-evidence assessments: Harmonization of Neurodevelopmental Environmental Epidemiology Studies (HONEES). *Neurotoxicol Teratol*. 2011;33(3):354-9. doi: 10.1016/j.ntt.2011.01.004. PubMed PMID: 21315817; PMCID: PMC3109230.
93. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpathi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). *The Lancet*. 2011;377(9778):1663-72. doi: 10.1016/s0140-6736(11)60355-3.
94. Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. *J Biomed Biotechnol*. 2011;2011:187103. Epub 2011/03/16. doi: 10.1155/2011/187103. PubMed PMID: 21403873; PMCID: PMC3051160.

95. Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger SD, Shulkin BL, Miller JH, Files B, Lane PA, Thompson BW, Miller ST, Ware RE, Baby HUG. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. *Blood*. 2011;117(9):2614-7. doi: 10.1182/blood-2010-04-278747. PubMed PMID: 21217080; PMCID: PMC3062353.
96. Mattison DR, Plant TM, Lin HM, Chen HC, Chen JJ, Twaddle NC, Doerge D, Slikker W, Jr., Patton RE, Hotchkiss CE, Callicott RJ, Schrader SM, Turner TW, Kesner JS, Vitiello B, Petibone DM, Morris SM. Pubertal delay in male nonhuman primates (*Macaca mulatta*) treated with methylphenidate. *Proc Natl Acad Sci U S A*. 2011;108(39):16301-6. doi: 10.1073/pnas.1102187108. PubMed PMID: 21930929; PMCID: PMC3182701.
97. Malek A, Mattison DR. Drugs and medicines in pregnancy: the placental disposition of opioids. *Curr Pharm Biotechnol*. 2011;12(5):797-803. Epub 2011/04/13. doi: BSP/CPB/E-Pub/00096-12-1 [pii]. PubMed PMID: 21480827.
98. Goodman M, Squibb K, Youngstrom E, Anthony LG, Kenworthy L, Lipkin PH, Mattison DR, LaKind JS. Using systematic reviews and meta-analyses to support regulatory decision making for neurotoxicants: lessons learned from a case study of PCBs. *Ciencia & saude coletiva*. 2011;16(7):3207-20. PubMed PMID: 21808908.
99. Feghali MN, Mattison DR. Clinical therapeutics in pregnancy. *J Biomed Biotechnol*. 2011;2011:783528. doi: 10.1155/2011/783528. PubMed PMID: 21785566; PMCID: PMC3139199.
100. Darney S, Fowler B, Grandjean P, Heindel J, Mattison D, Slikker W, Jr. Prenatal Programming and Toxicity II (PPTOX II): role of environmental stressors in the developmental origins of disease. *Reprod Toxicol*. 2011;31(3):271. Epub 2010/11/03. doi: 10.1016/j.reprotox.2010.10.010. PubMed PMID: 21035539.
101. Beigi RH, Han K, Venkataramanan R, Hankins GD, Clark S, Hebert MF, Easterling T, Zajicek A, Ren Z, Mattison DR, Caritis SN, Obstetric-Fetal Pharmacology Research Units N. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. *Am J Obstet Gynecol*. 2011;204(6 Suppl 1):S84-8. doi: 10.1016/j.ajog.2011.03.002. PubMed PMID: 21492826; PMCID: PMC3111757.
102. Youngstrom E, LaKind JS, Kenworthy L, Lipkin PH, Goodman M, Squibb K, Mattison DR, Anthony BJ, Anthony LG. Advancing the selection of neurodevelopmental measures in epidemiological studies of environmental chemical exposure and health effects. *Int J Environ Res Public Health*. 2010;7(1):229-68. Epub 2010/03/03. doi: 10.3390/ijerph7010229. PubMed PMID: 20195443; PMCID: PMC2819786.
103. Xiong X, Harville EW, Mattison DR, Elkind-Hirsch K, Pridjian G, Buekens P. Hurricane Katrina experience and the risk of post-traumatic stress disorder and depression among pregnant women. *Am J Disaster Med*. 2010;5(3):181-7. PubMed PMID: 20701175; PMCID: PMC3501144.
104. Welsh T, Tan HQ, Yi LJ, Mattison D, Caritis S, Mesiano S. Prophylactic 17 alpha-Hydroxyprogesterone Caproate Treatment Does Not Affect Gestation Length of in the Guinea Pig. *Reproductive Sciences*. 2010;17(3):283A-A. PubMed PMID: WOS:000275558601233.
105. Sharma S, Ellis EC, Dorko K, Zhang S, Mattison DR, Caritis SN, Venkataramanan R, Strom SC. Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes. *Drug Metab Dispos*. 2010;38(5):723-7. doi: 10.1124/dmd.109.029918. PubMed PMID: 20097724; PMCID: PMC2872946.
106. Rodriguez JS, Morris SM, Hotchkiss CE, Doerge DR, Allen RR, Mattison DR, Paule MG. The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys. *Neurotoxicol Teratol*. 2010;32(2):142-51. Epub 2009/09/10. doi: 10.1016/j.ntt.2009.08.011. PubMed PMID: 19737611; PMCID: PMC2942084.
107. Mattison DR. Research on cytogenetic risk of ADHD treatments in children. *J Atten Disord*. 2010;14(3):203-4. Epub 2010/10/28. doi: 10.1177/1087054710381477. PubMed PMID: 20978275.

108. Mattison DR. Environmental exposures and development. *Curr Opin Pediatr*. 2010;22(2):208-18. Epub 2010/03/11. doi: 10.1097/MOP.0b013e32833779bf. PubMed PMID: 20216314; PMCID: PMC2887611.
109. Mattison DR. Improving Pediatric Drug Development: Challenges, Opportunities and Lessons Learned. *Frontiers in Pharmacology*. 2010;1. doi: 10.3389/fphar.2010.00127.
110. Malek A, Mattison DR. Drug development for use during pregnancy: Impact of the placenta. *Expert Review of Obstetrics and Gynecology*. 2010;5(4):437-54.
111. LaKind JS, Youngstrom E, Goodman M, Squibb K, Lipkin PH, Anthony LG, Kenworthy L, Mattison DR. A multidisciplinary approach to advancing the science of neurodevelopmental testing in cohorts of infants and young children. *Neurotoxicology and Teratology*. 2010;32(4):505-6. doi: 10.1016/j.ntt.2010.04.035. PubMed PMID: WOS:000279528000043.
112. Koren G, Clark S, Hankins GD, Caritis SN, Miodovnik M, Umans JG, Mattison DR. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. *Am J Obstet Gynecol*. 2010;203(6):571 e1-7. Epub 2010/09/17. doi: 10.1016/j.ajog.2010.07.030. PubMed PMID: 20843504.
113. Kenworthy L, Anthony LG, Goodman M, LaKind JS, Lipkin PH, Mattison DR, Squibb K, Youngstrom E. Getting the biggest bang for your buck: Choosing neurodevelopmental tests that maximize power. *Neurotoxicology and Teratology*. 2010;32(4):506-. doi: 10.1016/j.ntt.2010.04.036. PubMed PMID: WOS:000279528000044.
114. Goodman M, Squibb K, Youngstrom E, Anthony LG, Kenworthy L, Lipkin PH, Mattison DR, Lakind JS. Using systematic reviews and meta-analyses to support regulatory decision making for neurotoxicants: lessons learned from a case study of PCBs. *Environ Health Perspect*. 2010;118(6):727-34. Epub 2010/02/24. doi: 10.1289/ehp.0901835. PubMed PMID: 20176542; PMCID: PMC2898846.
115. Goodman M, Lakind J, Squibb K, Youngstrom E, Anthony L, Kenworthy L, Lipkin P, Mattison D. Weight-of-the-Evidence Assessment in Neurodevelopmental Epidemiology: A Plea for Consistency. *Birth Defects Research Part a-Clinical and Molecular Teratology*. 2010;88(5):339-. PubMed PMID: WOS:000278320600030.
116. Anthony LG, Youngstrom EA, Kenworthy LE, LaKind JS, Goodman M, Squibb KS, Lipkin PH, Mattison DR. Threats to study validity: The Flynn Effect, examiner drift, confounders, lost in translation, and other important considerations. *Neurotoxicology and Teratology*. 2010;32(4):506-7. doi: 10.1016/j.ntt.2010.04.037. PubMed PMID: WOS:000279528000045.
117. Zharikova OL, Fokina VM, Nanovskaya TN, Hill RA, Mattison DR, Hankins GD, Ahmed MS. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. *Biochem Pharmacol*. 2009;78(12):1483-90. doi: 10.1016/j.bcp.2009.08.003. PubMed PMID: 19679108; PMCID: PMC3982398.
118. Valluri SC, Zito JM, Safer DJ, Zuckerman IH, Mullins CD, Korelitz JJ, Mattison DR, Taylor-Zapata P. Impact of the 2004 FDA Pediatric Suicidality Warnings on Antidepressant and Psychotherapy Treatment for New-Onset Depression. *Journal of Child and Adolescent Psychopharmacology*. 2009;19(6):784-. PubMed PMID: WOS:000273053600030.
119. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet*. 2009;48(3):143-57. Epub 2009/04/24. doi: 10.2165/00003088-200948030-00001. PubMed PMID: 19385708; PMCID: PMC3644551.
120. Sharma S, Venkataramanan R, Caritis SN, Mattison DR, Strom S. Disposition of 17 alpha-Hydroxyprogesterone Caproate (17-OHPC) in Human Fetal. *Reproductive Sciences*. 2009;16(3):216A-7A. PubMed PMID: WOS:000263609800516.
121. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. *N Engl J Med*. 2009;360(15):1574-5. Epub 2009/04/10. doi: 10.1056/NEJMc0809750. PubMed PMID: 19357418.

122. Rivkees SA, Mattison DR. Propylthiouracil (PTU) Hepatotoxicity in Children and Recommendations for Discontinuation of Use. *Int J Pediatr Endocrinol.* 2009;2009:132041. Epub 2009/12/01. doi: 10.1155/2009/132041. PubMed PMID: 19946400; PMCID: PMC2777303.
123. Patterson T, Li M, Morris S, Rodriguez J, Slikker W, Mattison D, Paule M. The effects of chronic methylphenidate treatment on the performance of rhesus monkeys in the NCTR operant test battery. *Neurotoxicology and Teratology.* 2009;31(4):248-. doi: 10.1016/j.ntt.2009.04.049. PubMed PMID: WOS:000267253900052.
124. Morris SM, Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Manjanatha MG, Shelton SD, Doerge DR, Twaddle NC, Chen JJ, Lin CJ, Paule MG, Slikker W, Jr., Hotchkiss CE, Petibone D, Tucker JD, Mattison DR. The genetic toxicology of methylphenidate hydrochloride in non-human primates. *Mutat Res.* 2009;673(1):59-66. Epub 2009/01/13. doi: 10.1016/j.mrgentox.2008.12.001. PubMed PMID: 19135169.
125. Manjanatha MG, Shelton SD, Dobrovolsky VN, Shaddock JG, McGarrity LG, Twaddle NW, Moore MM, Mattison DR, Slikker W, Jr., Morris SM. Evaluation of mutagenic mode of action in Big Blue mice fed methylphenidate for 24 weeks. *Mutat Res.* 2009;680(1-2):43-8. Epub 2009/09/26. doi: 10.1016/j.mrgentox.2009.09.004. PubMed PMID: 19778631.
126. LaKind JS, Berlin CM, Mattison DR. Regarding: The Heart of the Matter on Breastmilk and Environmental Chemicals: Essential Points for Healthcare Providers and New Parents Response. *Breastfeeding Medicine.* 2009;4(2):127-. doi: 10.1089/bfm.2009.0011. PubMed PMID: WOS:000276674000014.
127. Kapogiannis BG, Mattison DR. Adolescents in Clinical Trials (vol 84, pg 655, 2008). *Clinical Pharmacology & Therapeutics.* 2009;85(2):222-. PubMed PMID: WOS:000262816600027.
128. Hebert MF, Ma X, Narahariseti SB, Krudys KM, Umans JG, Hankins GD, Caritis SN, Miodovnik M, Mattison DR, Unadkat JD, Kelly EJ, Blough D, Cobelli C, Ahmed MS, Snodgrass WR, Carr DB, Easterling TR, Vicini P, Obstetric-Fetal Pharmacology Research Unit N. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. *Clin Pharmacol Ther.* 2009;85(6):607-14. doi: 10.1038/clpt.2009.5. PubMed PMID: 19295505; PMCID: PMC2684566.
129. Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Manjanatha MG, Miura D, Uchikawa M, Mattison DR, Morris SM. Evaluation of *Macaca mulatta* as a model for genotoxicity studies. *Mutat Res.* 2009;673(1):21-8. Epub 2008/12/17. doi: 10.1016/j.mrgentox.2008.11.006. PubMed PMID: 19073277.
130. Dinauer C, Korelitz JJ, Mattison DR, Zito J, Rivkees SA. Prevalence and treatment of childhood Graves' disease in the United States. *Hormone Research.* 2009;72:172-. PubMed PMID: WOS:000270489900506.
131. Cunningham AR, Carrasquer CA, Mattison DR. A categorical structure-activity relationship analysis of the developmental toxicity of antithyroid drugs. *Int J Pediatr Endocrinol.* 2009;2009:936154. doi: 10.1155/2009/936154. PubMed PMID: 20111734; PMCID: PMC2810459.
132. Caritis SN, Sharma S, Zhang S, Miodovnik M, Hankins GDV, Hebert M, Mattison DR, Venkataramanan R. Pharmacokinetics (PK) of 17-Hydroxyprogesterone Caproate (17-OHPC) in Singleton Gestation. *Reproductive Sciences.* 2009;16(3):85A-A. PubMed PMID: WOS:000263609800059.
133. Caritis SN, Sharma S, Zhang S, Mattison DR, Miodovnik M, Hankins GDV, Hebert MF, Venkataramanan R. Placental Transfer of 17-alpha Hydroxyprogesterone Caproate (17-OHPC). *Reproductive Sciences.* 2009;16(3):217A-A. PubMed PMID: WOS:000263609800517.
134. Buchanan ML, Easterling TR, Carr DB, Shen DD, Risler LJ, Nelson WL, Mattison DR, Hebert MF. Clonidine pharmacokinetics in pregnancy. *Drug Metab Dispos.* 2009;37(4):702-5. doi: 10.1124/dmd.108.024984. PubMed PMID: 19116263; PMCID: PMC2680537.
135. Brunstrom-Hernandez JE, Thio LL, Lowenhaupt S, Krach LE, Kobayashi A, McLaughlin J, Tilton A, Stevenson R, Haake RJ, Mattison DR, Best Network USA. Effects of Oral Baclofen in Children with Cerebral Palsy. *Annals of Neurology.* 2009;66:S115-S. PubMed PMID: WOS:000270757700373.

136. Brunstrom-Hernandez JE, Stashinko E, Krach LE, Thio LL, Kuroda M, Bjornson K, Hoon A, Gaebler D, Haake RJ, Mattison DR, USA BN. Baclofen Efficacy and Safety Trials (BEST): Variability in Dosing Practices of Oral Baclofen for Children with Cerebral Palsy. *Annals of Neurology*. 2009;66:S115-S. PubMed PMID: WOS:000270757700372.
137. Zito JM, Valluri S, Hundley SD, Safer DJ, Gardner JF, Maneval M, Korelitz JJ, McNally DL, Taylor-Zapata P, Mattison DR. Impact of comorbid disruptive disorders on pharmacotherapy for attention-deficit/hyperactivity disorder in publicly-insured US youth. *Pharmacoepidemiology and Drug Safety*. 2008;17:S198-S9. PubMed PMID: WOS:000258420100452.
138. Zhang S, Mada SR, Sharma S, Torch M, Mattison D, Caritis S, Venkataramanan R. Simultaneous quantitation of 17 α -hydroxyprogesterone caproate, 17 α -hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). *Journal of Pharmaceutical and Biomedical Analysis*. 2008;48(4):1174-80.
139. Yan R, Nanovskaya TN, Zharikova OL, Mattison DR, Hankins GD, Ahmed MS. Metabolism of 17 α -hydroxyprogesterone caproate by hepatic and placental microsomes of human and baboons. *Biochem Pharmacol*. 2008;75(9):1848-57. doi: 10.1016/j.bcp.2008.01.013. PubMed PMID: 18329004; PMCID: PMC2408387.
140. Xiong X, Harville EW, Mattison DR, Elkind-Hirsch K, Pridjian G, Buekens P. Experience of Hurricane Katrina and risk of post-traumatic stress disorder and depression among pregnant women. *American Journal of Epidemiology*. 2008;167(11):S21-S. PubMed PMID: WOS:000256310200084.
141. Xiong X, Harville EW, Mattison DR, Elkind-Hirsch K, Pridjian G, Buekens P. Hurricane Katrina experience, post-traumatic stress disorder and birth outcome. *American Journal of Epidemiology*. 2008;167(11):S20-S. PubMed PMID: WOS:000256310200081.
142. Xiong X, Harville EW, Mattison DR, Elkind-Hirsch K, Pridjian G, Buekens P. Exposure to Hurricane Katrina, post-traumatic stress disorder and birth outcomes. *Am J Med Sci*. 2008;336(2):111-5. Epub 2008/08/16. doi: 10.1097/MAJ.0b013e318180f21c. PubMed PMID: 18703903; PMCID: PMC2635112.
143. Witt KL, Shelby MD, Itchon-Ramos N, Faircloth M, Kissling GE, Chrisman AK, Ravi H, Murli H, Mattison DR, Kollins SH. Chromosomal aberrations, sister chromatid exchanges, and micronuclei in lymphocytes of pediatric ADHD patients treated with stimulant drugs. *Environmental and Molecular Mutagenesis*. 2008;49(7):528-. PubMed PMID: WOS:000258725800052.
144. Witt KL, Shelby MD, Itchon-Ramos N, Faircloth M, Kissling GE, Chrisman AK, Ravi H, Murli H, Mattison DR, Kollins SH. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. *J Am Acad Child Adolesc Psychiatry*. 2008;47(12):1375-83. Epub 2008/11/04. doi: 10.1097/CHI.0b013e3181893620. PubMed PMID: 18978633; PMCID: PMC2807376.
145. Stillerman KP, Mattison DR, Giudice LC, Woodruff TJ. Environmental exposures and adverse pregnancy outcomes: a review of the science. *Reprod Sci*. 2008;15(7):631-50. Epub 2008/10/07. doi: 10.1177/1933719108322436. PubMed PMID: 18836129.
146. Slikker W, Mattison DR, Patterson TA, Paule MG, Li M, Doerge D, Twaddle N, Hotchkiss CE, Chen JJ, Morris SM. Pharmacological effects of methylphenidate in the developing primate. *Environmental and Molecular Mutagenesis*. 2008;49(7):529-. PubMed PMID: WOS:000258725800056.
147. Simhan HN, Chiao JP, Mattison DR, Caritis SN. Human decidual cell Toll-like receptor signaling in response to endotoxin: the effect of progestins. *Am J Obstet Gynecol*. 2008;198(1):119 e1-4. Epub 2007/10/16. doi: 10.1016/j.ajog.2007.06.022. PubMed PMID: 17936235; PMCID: PMC2712725.
148. Shelton SD, Manjanatha MG, Mattison DR, Morris SM. Evaluation of cII mutations in Big Blue mice fed methylphenidate hydrochloride for up to 24 weeks. *Environmental and Molecular Mutagenesis*. 2008;49(7):561-. PubMed PMID: WOS:000258725800176.
149. Sharma S, Ou J, Strom S, Mattison D, Caritis S, Venkataramanan R. Identification of enzymes involved in the metabolism of 17 α -hydroxyprogesterone caproate: An effective agent for prevention of preterm birth. *Drug Metabolism and Disposition*. 2008;36(9):1896-902.

150. Ravindran S, Zharikova O, Nanovskaya T, Hill R, Mattison D, Hankins G, Ahmed M. MEDI 132- Investigation of glyburide and its metabolites in urine and plasma of pregnant patients under treatment for gestational diabetes. Abstracts of Papers of the American Chemical Society. 2008;235. PubMed PMID: WOS:000271775107284.
151. Petibone DM, Morris SM, Hotchkiss CE, Mattison DR, Tucker JD. Technique for culturing Macaca mulatta peripheral blood lymphocytes for fluorescence in situ hybridization of whole chromosome paints. *Mutat Res*. 2008;653(1-2):76-81. Epub 2008/05/24. doi: 10.1016/j.mrgentox.2008.03.012. PubMed PMID: 18499509.
152. Nanovskaya TN, Patrikeeva S, Hemauer S, Fokina V, Mattison D, Hankins GD, Ahmed MS, Network O. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. *J Matern Fetal Neonatal Med*. 2008;21(3):197-207. doi: 10.1080/14767050801929901. PubMed PMID: 18297575.
153. Morris SM, Hotchkiss CE, Bishop ME, Dobrovolsky V, Doerge D, Twaddle N, Chen JJ, Lin CJ, Paule M, Slikker W, Petibone DM, Tucker JD, Manjanatha MG, Mattison DR. The genetic toxicology of methiphenidate hydrochloride in non-human primates. *Environmental and Molecular Mutagenesis*. 2008;49(7):529-. PubMed PMID: WOS:000258725800053.
154. Manjanatha MG, Shelton SD, Dobrovolsky VN, Shaddock JG, McGarrity LY, Lin CJ, Chen JJ, Mattison DR, Morris SM. Genotoxicity of methylphenidate hydrochloride in big blue mice. *Environmental and Molecular Mutagenesis*. 2008;49(7):529-. PubMed PMID: WOS:000258725800054.
155. Manjanatha MG, Shelton SD, Dobrovolsky VN, Shaddock JG, McGarrity LG, Doerge DR, Twaddle NW, Lin CJ, Chen JJ, Mattison DR, Morris SM. Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice. *Environ Mol Mutagen*. 2008;49(8):585-93. Epub 2008/07/12. doi: 10.1002/em.20407. PubMed PMID: 18618596.
156. Ma X, Vicini P, Krudys KM, Co-Belli C, Umans J, Hankins GD, Caritis SN, Miodovnik M, Mattison DR, Carr DR, Easterling TR, Hebert MF. Insulin sensitivity, beta-cell function and disposition index in gestational diabetes treated with glyburide monotherapy. *Diabetes*. 2008;57:A72-A. PubMed PMID: WOS:000256612000240.
157. LaKind JS, Berlin CM, Mattison DR. The heart of the matter on breastmilk and environmental chemicals: essential points for healthcare providers and new parents. *Breastfeed Med*. 2008;3(4):251-9. Epub 2008/12/18. doi: 10.1089/bfm.2008.0121. PubMed PMID: 19086828.
158. Korelitz JJ, Zito JM, Gavin NI, Masters MN, McNally D, Irwin DE, Kelleher K, Bethel J, Xu Y, Rubin J, Mattison DR. Asthma-related medication use among children in the United States. *Ann Allergy Asthma Immunol*. 2008;100(3):222-9. Epub 2008/04/23. doi: 10.1016/S1081-1206(10)60446-2. PubMed PMID: 18426141.
159. Kapogiannis BG, Mattison DR. Adolescents in clinical trials. *Clin Pharmacol Ther*. 2008;84(6):655-9. Epub 2008/11/15. doi: 10.1038/clpt.2008.191. PubMed PMID: 19008903.
160. Jain S, Zharikova OL, Ravindran S, Nanovskaya TN, Mattison DR, Hankins GD, Ahmed MS. Glyburide metabolism by placentas of healthy and gestational diabetics. *Am J Perinatol*. 2008;25(3):169-74. doi: 10.1055/s-2008-1061503. PubMed PMID: 18300189.
161. Jacobson-Kram D, Mattison D, Shelby M, Slikker W, Tice R, Witt K. Methylphenidate and chromosome damage. *Cancer Lett*. 2008;260(1-2):216-8. doi: 10.1016/j.canlet.2007.10.017. PubMed PMID: 18055105.
162. Hemauer SJ, Yan R, Patrikeeva SL, Mattison DR, Hankins GD, Ahmed MS, Nanovskaya TN. Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate. *Am J Obstet Gynecol*. 2008;199(2):169 e1-5. Epub 2008/08/05. doi: 10.1016/j.ajog.2007.11.065. PubMed PMID: 18674659; PMCID: PMC4046337.
163. Giacoia GP, Taylor-Zapata P, Mattison D. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: Selected Reports from Working

- Groups. *Clinical Therapeutics*. 2008;30(11):2097-101. doi: 10.1016/j.clinthera.2008.11.017. PubMed PMID: WOS:000261811600014.
164. Giacoia GP, Taylor-Zapata P, Mattison D. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups. *Clin Ther*. United States 2008. p. 2097-101.
165. Dobrovolsky VN, Shaddock JG, Manjanatha MG, Miura D, Mattison DR, Morris SM. Genotoxicity of methylphenidate hydrochloride in the rhesus monkey. *Environmental and Molecular Mutagenesis*. 2008;49(7):565-. PubMed PMID: WOS:000258725800191.
166. Bishop ME, Hotchkiss CE, Lin CJ, Chen JJ, Mattison DR, Morris SM. Flow cytometric determination of the micronucleus frequency in juvenile rhesus monkeys chronically exposed to methylphenidate hydrochloride. *Environmental and Molecular Mutagenesis*. 2008;49(7):564-. PubMed PMID: WOS:000258725800188.
167. Zito JM, Safer DJ, Valluri S, Gardner JF, Korelitz JJ, Mattison DR. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. *J Child Adolesc Psychopharmacol*. 2007;17(2):195-203. Epub 2007/05/11. doi: 10.1089/cap.2007.0006. PubMed PMID: 17489714.
168. Zito JM, Korelitz JJ, Valluri S, Gardner JF, Bethel J, Mattison DR. Comparing prevalence estimates from US claims data by two methods. *Pharmacoepidemiology and Drug Safety*. 2007;16:S120-S. PubMed PMID: WOS:000248820200253.
169. Zharikova O, Fokina V, Nanovskaya T, Ravindran S, Hill R, Mattison D, Hankins GDV, Ahmed M. Identification of the major human hepatic and placental enzymes responsible for the metabolism of glyburide. *American Journal of Obstetrics and Gynecology*. 2007;197(6):S111-S. doi: 10.1016/j.ajog.2007.10.380. PubMed PMID: WOS:000251708500362.
170. Zhang S, Mada SR, Mattison D, Caritis S, Venkataramanan R, Network O. Development and validation of a high-performance liquid chromatography-mass spectrometric assay for the determination of 17alpha-hydroxyprogesterone caproate (17-OHPC) in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2007;856(1-2):141-7. doi: 10.1016/j.jchromb.2007.05.028. PubMed PMID: 17576102; PMCID: PMC4398913.
171. Yan R, Nanovskaya T, Mattison D, Hankins GDV, Ahmed M. Metabolism of 17-hydroxyprogesterone caproate by human hepatic and placental microsomes. *American Journal of Obstetrics and Gynecology*. 2007;197(6):S48-S. doi: 10.1016/j.ajog.2007.10.135. PubMed PMID: WOS:000251708500126.
172. Xiong X, Harville EW, Buekens P, Mattison DR, Elkind-Hirsch K, Pridjian G. Post-traumatic stress disorder and depression in pregnant women affected by Hurricane Katrina. *American Journal of Epidemiology*. 2007;165(11):S22-S. PubMed PMID: WOS:000247034500087.
173. Taylor-Zapata P, Mattison DR. Making progress for how medicines are used in children. *Arch Pediatr Adolesc Med*. 2007;161(9):916; author reply -7. Epub 2007/09/05. doi: 10.1001/archpedi.161.9.916-a. PubMed PMID: 17768295.
174. Petibone DM, Morris SM, Hotchkiss CE, Mattison DR, Tucker JD. Technique for culturing *Macaca mulatta* peripheral lymphocytes for FISH and classical cytogenetic analyses. *Environmental and Molecular Mutagenesis*. 2007;48(7):620-. PubMed PMID: WOS:000248865500226.
175. Myers M, Bishop M, Hotchkiss C, Lin CJ, Chen J, Mattison D, Morris S. Frequency of micronucleated erythrocytes in the peripheral blood of juvenile male rhesus monkeys, *Macaca mulatta*, determined by flow cytometry. *Environmental and Molecular Mutagenesis*. 2007;48(7):589-. PubMed PMID: WOS:000248865500158.
176. McClure EM, Goldenberg RL, Brandes N, Darmstadt GL, Wright LL, Group CHXW, Armbruster D, Biggar R, Carpenter J, Free MJ, Mattison D, Mathai M, Moss N, Mullany LC, Schrag S, Tielsch J, Tolosa J, Wall SN, Schuchat A, Smine A. The use of chlorhexidine to reduce maternal and neonatal mortality and

- morbidity in low-resource settings. *Int J Gynaecol Obstet.* 2007;97(2):89-94. doi: 10.1016/j.ijgo.2007.01.014. PubMed PMID: 17399714; PMCID: PMC2727736.
177. Mattison DR. Obstetric and pediatric drug development: Opportunities and challenges facing therapeutic advances in neglected populations. *Birth Defects Research Part a-Clinical and Molecular Teratology.* 2007;79(5):404-. PubMed PMID: WOS:000246425800093.
178. Koren G, Kramer M, Mattison D. The Summer Institutes in Maternal-Fetal Pharmacology: building critical mass in a neglected area. *J Obstet Gynaecol Can.* 2007;29(7):544-5. PubMed PMID: 17623565.
179. Hemauer S, Yan R, Patrikeeva S, Mattison D, Hankins GDV, Ahmed M, Nanovskaya T. Metabolism of 17-hydroxyprogesterone caproate by the dually perfused human placental lobule. *American Journal of Obstetrics and Gynecology.* 2007;197(6):S45-S. doi: 10.1016/j.ajog.2007.10.124. PubMed PMID: WOS:000251708500115.
180. Hebert MF, Naraharisett SB, Ma X, Krudys KM, Umans J, Hankins GDV, Caritis S, Miodovnik M, Mattison DR, Unadkat J, Easterling TR, Vicini P. Are we guessing glyburide dosage in the treatment of gestational diabetes (GDM)? The pharmacological evidence for better clinical practice. *American Journal of Obstetrics and Gynecology.* 2007;197(6):S25-S. doi: 10.1016/j.ajog.2007.10.060. PubMed PMID: WOS:000251708500056.
181. Giacoia GP, Taylor-Zapata P, Mattison D. Need for appropriate formulations for children: The National Institute of Child Health and Human Development - Pediatric Formulations Initiative, part 1. *International Journal of Pharmaceutical Compounding.* 2007;11(1):5-8.
182. Giacoia GP, Taylor-Zapata P, Mattison D. Need for appropriate formulations for children: The National Institute of Child Health and Human Development - Pediatric formulations initiative, Part 2. *International Journal of Pharmaceutical Compounding.* 2007;11(3):220-1.
183. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN, Obstetric-Fetal Pharmacology Research Unit N. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. *Am J Obstet Gynecol.* 2007;197(6):599 e1-7. doi: 10.1016/j.ajog.2007.05.024. PubMed PMID: 18060946; PMCID: PMC2278032.
184. Miller RK, Wilson D, Salafia CM, Ornoy A, Yacobi S, Richards S, Adair D, Lin ZQ, Plessinger MA, Polliotti BM, Hashem M, Asai M, Ozcan T, Woodall A, D'Gregorio RP, Camerio M, Malek A, Genbacev O, Mattison DR, Panigel M. Environmental impact on placental function in diseases of pregnancy. *Placenta.* 2006;27(9-10):A6-A. PubMed PMID: WOS:000240312200032.
185. Mattison D, Zajicek A. Gaps in knowledge in treating pregnant women. *Gend Med.* 2006;3(3):169-82. PubMed PMID: 17081950.
186. Giacoia GP, Mattison DR. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II. *Clin Ther.* 2006;28(9):1337-41. Epub 2006/10/26. doi: 10.1016/j.clinthera.2006.09.003. PubMed PMID: 17062307.
187. Giacoia GP, Birenbaum DL, Sachs HC, Mattison DR. The newborn drug development initiative. *Pediatrics.* 2006;117(3 Pt 2):S1-8. Epub 2006/06/17. doi: 10.1542/peds.2005-0620B. PubMed PMID: 16777817.
188. Slikker W, Jr., Young JF, Corley RA, Dorman DC, Conolly RB, Knudsen TB, Erstad BL, Luecke RH, Faustman EM, Timchalk C, Mattison DR. Improving predictive modeling in pediatric drug development: pharmacokinetics, pharmacodynamics, and mechanistic modeling. *Ann N Y Acad Sci.* 2005;1053:505-18. Epub 2005/09/24. doi: 10.1196/annals.1344.044. PubMed PMID: 16179559.
189. Luderer U. Endocrine and Reproductive Disorders. *Textbook of Clinical Occupational and Environmental Medicine.* 2005:609-43. doi: 10.1016/b978-0-7216-8974-6.50031-2.

190. Giacoia GP, Mattison DR. Newborns and drug studies: the NICHD/FDA newborn drug development initiative. *Clin Ther.* 2005;27(6):796-813. Epub 2005/08/25. doi: 10.1016/j.clinthera.2005.06.008. PubMed PMID: 16117987.
191. Mattison DR. Introduction to the session, tribute to David Rall and overview of the process. *Neurotoxicology.* 2004;25(4):699-. PubMed PMID: WOS:000222121900107.
192. Gray GM, Cohen JT, Cunha G, Hughes C, McConnell EE, Rhomberg L, Sipes IG, Mattison D. Weight of the evidence evaluation of low-dose reproductive and developmental effects of bisphenol A. *Human and Ecological Risk Assessment.* 2004;10(5):875-921.
193. Russell RB, Petrini JR, Damus K, Mattison DR, Schwarz RH. The changing epidemiology of multiple births in the United States. *Obstet Gynecol.* 2003;101(1):129-35. Epub 2003/01/09. doi: S0029784402023165 [pii]. PubMed PMID: 12517657.
194. Olshan AF, Kimmel G, Mattison D. Risk assessment. *Advances in Experimental Medicine and Biology*2003. p. 269-70.
195. Mattison DR, Institute of Medicine (U.S.). Roundtable on Environmental Health Sciences Research and Medicine., National Institute of Environmental Health Sciences. The role of environmental hazards in premature birth : workshop summary. Washington, D.C.: National Academies Press; 2003. xvii, 127 p. p.
196. Mattison DR. Sex matters: "Gender" differences in toxicology. *Toxicology.* 2003;192(1):59-60. PubMed PMID: WOS:000185769800012.
197. Mattison D. Sex matters: "Gender" differences in toxicology. *American Journal of Epidemiology.* 2003;157(11):S70-S. PubMed PMID: WOS:000183385400270.
198. Birenbaum D, Mattison DR. Analgesics for the treatment of pain in children. *N Engl J Med.* 2003;348(10):959-60; author -60. doi: 10.1056/NEJM200303063481020. PubMed PMID: 12621144.
199. Petrini J, Damus K, Russell R, Poschman K, Davidoff MJ, Mattison D. Contribution of birth defects to infant mortality in the United States. *Teratology.* 2002;66 Suppl 1(SUPPL. 1):S3-6. doi: 10.1002/tera.90002. PubMed PMID: 12239736.
200. Olshan AF, Kimmel G, Mattison D. Risk assessment. In: Robaire B, Hales BF, editors. *Advances in Male Mediated Developmental Toxicity*2002. p. 269-70.
201. Mattison DR, Leavitt R, Landesman LY, Rosenfield A. Disaster planning: Preparing your practice for a disaster. *Contemporary Ob/Gyn.* 2002;47(2):54-66.
202. Mattison D, VandenBosch TM, Soskolne E, Ward B. Adolescent female assent in clinical trials: A model assent process. *Drug Information Journal.* 2002;36(1):21-30. doi: 10.1177/009286150203600106. PubMed PMID: WOS:000174269100006.
203. Landrigan PJ, Sonawane B, Mattison D, McCally M, Garg A. Chemical contaminants in breast milk and their impacts on children's health: An overview. *Environmental Health Perspectives.* 2002;110(6):A313-A5.
204. Davidoff MJ, Petrini J, Damus K, Russell RB, Mattison D. Neural tube defect-specific infant mortality in the United States. *Teratology.* 2002;66 Suppl 1(SUPPL. 1):S17-22. doi: 10.1002/tera.90005. PubMed PMID: 12239739.
205. Russell RB, Petrini J, Damus K, Alter C, Schwarz R, Mattison D. Differential birthweight-specific infant mortality by plurality: Things are changing. *American Journal of Epidemiology.* 2001;153(11):S146-S. PubMed PMID: WOS:000169006400502.
206. Mattison DR, Damus K, Fiore E, Petrini J, Alter C. Preterm delivery: a public health perspective. *Paediatr Perinat Epidemiol.* 2001;15 Suppl 2:7-16. PubMed PMID: 11520396.
207. Landrigan PJ, Mattison DR, Boardman B, Bruckner JV, Jackson RJ, Karol MH, Krewski D, Weil WB. Comments on "Children's health, susceptibility, and regulatory approaches to reducing risk from chemical carcinogens". *Environmental health perspectives.* 2001;109(9):A412-3. PubMed PMID: 595480434; 11673132.

208. Johnston RB, Jr., Williams MA, Hogue CJ, Mattison DR. Overview: new perspectives on the stubborn challenge of preterm birth. *Paediatr Perinat Epidemiol.* 2001;15 Suppl 2:3-6. PubMed PMID: 11520395.
209. Campbell RK. The unnecessary epidemic of folic acid-preventable spina bifida and anencephaly. *Pediatrics.* 2001;108(4):1048-50. PubMed PMID: 11589212.
210. Brent RL, Oakley GP, Mattison DR. The unnecessary epidemic of folic acid-preventable spina bifida and anencephaly - Reply. *Pediatrics.* 2001;108(4):1048-50. PubMed PMID: WOS:000171319600064.
211. Mazumdar S, Xu Y, Mattison DR, Sussman NB, Arena VC. 22 Statistical methods for reproductive risk assessment. *Handbook of Statistics2000.* p. 649-71.
212. Mattison DR. Folic acid requirements for women of childbearing age (vol 60, pg 2510, 1999). *American Family Physician.* 2000;61(8):2344-. PubMed PMID: WOS:000086673400009.
213. Kirby R, Petrini J, Alter C. Collecting and interpreting birth defects surveillance data by hispanic ethnicity: a comparative study. The Hispanic Ethnicity Birth Defects Workgroup. *Teratology.* 2000;61(1-2):21-7. doi: 10.1002/(SICI)1096-9926(200001/02)61:1/2<21::AID-TERA5>3.0.CO;2-X. PubMed PMID: 10603199.
214. Brent RL, Oakley GP, Jr., Mattison DR. The unnecessary epidemic of folic acid-preventable spina bifida and anencephaly. *Pediatrics.* 2000;106(4):825-7. PubMed PMID: 11015526.
215. Sussman NB, Mazumdar S, Mattison DR. Modeling adverse environmental impacts on the reproductive system. *J Womens Health.* 1999;8(2):217-26. doi: 10.1089/jwh.1999.8.217. PubMed PMID: 10100135.
216. Shine KI, Mattison DR. IOM on core functions. *Public Health Rep.* 1999;114(1):6. PubMed PMID: 9925162; PMCID: PMC1308338.
217. Petrini J, Damus K, Johnston R, Mattison D. Knowledge and use of folic acid by women of childbearing age-United States, 1995 and 1998 (Reprinted from *MMWR*, vol 48, pg 325-327, 1999). *JAMA.* 1999;281(20):1883-4. PubMed PMID: WOS:000080427300008.
218. Mazumdar S, Xu YK, Mattison DR, Sussman N, Arena VC. Reproductive risk assessment with longitudinal data. Ahsanullah M, Yildirim F, editors1999. 59-75 p.
219. Mattison DR, Deen D, Jr., Hark L. Folic acid requirements for women of childbearing age [6] (multiple letters). *American Family Physician.* 1999;60(9):2510-5.
220. Institute of Medicine (U.S.). Committee on Environmental Justice., Health Sciences Policy Program (U.S.). *Toward environmental justice : research, education, and health policy needs.* Washington, D.C.: National Academy Press; 1999. xii, 137 p. p.
221. Gomez J, Macina OT, Mattison DR, Zhang YP, Klopman G, Rosenkranz HS. Structural determinants of developmental toxicity in hamsters. *Teratology.* 1999;60(4):190-205. Epub 1999/10/06. doi: 10.1002/(SICI)1096-9926(199910)60:4<190::AID-TERA3>3.0.CO;2-U. PubMed PMID: 10508972.
222. Coughlin SS, Katz WH, Mattison DR. Ethics instruction at schools of public health in the United States. Association of Schools of Public Health Education Committee. *Am J Public Health.* 1999;89(5):768-70. PubMed PMID: 10224994; PMCID: PMC1508720.
223. Rosenkranz HS, Zhang YP, Macina OT, Mattison DR, Klopman G. Human developmental toxicity and mutagenesis. *Mutat Res.* 1998;422(2):347-50. Epub 1998/12/05. doi: S0027510798001705 [pii]. PubMed PMID: 9838188.
224. Zhang YP, Macina OT, Rosenkranz HS, Karol MH, Mattison DR, Klopman G. Prediction of the metabolism and toxicological profiles of gasoline oxygenates. *Inhalation Toxicology.* 1997;9(3):237-54.
225. Mattison DR. Session IV: Implications of new approaches for improved risk assessment for developmental abnormalities. *Reproductive Toxicology.* 1997;11(2-3):437-41. doi: 10.1016/s0890-6238(97)89925-x. PubMed PMID: WOS:A1997WQ84000038.

226. Mattison D. Session IV: Implications of new approaches for improved risk assessment for developmental abnormalities. *Reproductive Toxicology*. 1997;11(2-3):437-41.
227. Ghanooni M, Mattison DR, Zhang YP, Macina OT, Rosenkranz HS, Klopman G. Structural determinants associated with risk of human developmental toxicity. *Am J Obstet Gynecol*. 1997;176(4):799-805; discussion -6. Epub 1997/04/01. doi: S0002-9378(97)70603-3 [pii]. PubMed PMID: 9125603.
228. Bolon B, Bucci TJ, Warbritton AR, Chen JJ, Mattison DR, Heindel JJ. Differential follicle counts as a screen for chemically induced ovarian toxicity in mice: results from continuous breeding bioassays. *Fundam Appl Toxicol*. 1997;39(1):1-10. Epub 1997/11/05. doi: S0272059097923381 [pii]. PubMed PMID: 9325022.
229. Schwetz BA, Mattison DR. Decision strategies in assessment of reproductive and developmental toxicology: A paradigm for safety evaluation. Alexander NJ, Wentz AC, editors 1996. 119-31 p.
230. Malek A, Miller RK, Mattison DR, Kennedy S, Panigel M, di Sant'Agnese PA, Jessee L. Energy charge monitoring via magnetic resonance spectroscopy ³¹P in the perfused human placenta: effects of cadmium, dinitrophenol and Iodoacetate. *Placenta*. 1996;17(7):495-506. doi: 10.1016/s0143-4004(96)90032-6. PubMed PMID: 686045481; 1996347159.
231. Malek A, Blann E, Mattison DR. Human placental transport of oxytocin. *J Matern Fetal Med*. 1996;5(5):245-55. Epub 1996/09/01. doi: 10.1002/(SICI)1520-6661(199609/10)5:5<245::AID-MFM3>3.0.CO;2-H. PubMed PMID: 8930795.
232. Mazumdar S, Mattison DR, Damaraju CV. TEMPORAL ISSUES IN REPRODUCTIVE RISK ASSESSMENT. *Inhalation Toxicology*. 1995;7(6):837-62. doi: 10.3109/08958379509012793. PubMed PMID: WOS:A1995RQ50800002.
233. Malek A, Miller RK, Mattison DR, Ceckler T, Panigel M, di Sant'Agnese PA, Jessee LN. Continuous measurement of ATP by ³¹P-NMR in term human dually perfused placenta in vitro: response to ischemia. *J Appl Physiol* (1985). 1995;78(5):1778-86. Epub 1995/05/01. PubMed PMID: 7649912.
234. Malek A, Ivy D, Blann E, Mattison DR. Impact of cocaine on human placental function using an in vitro perfusion system. *J Pharmacol Toxicol Methods*. 1995;33(4):213-9. Epub 1995/08/01. doi: 1056-8719(95)00018-D [pii]. PubMed PMID: 8527829.
235. Malek A, Blann E, Mattison DR. Continuous pO₂ monitoring during dual perfusion of the term human placenta in vitro. *Gynecol Obstet Invest*. 1995;39(1):28-33. Epub 1995/01/01. PubMed PMID: 7890249.
236. Lee Y, Buchanan BG, Mattison DM, Klopman G, Rosenkranz HS. Learning rules to predict rodent carcinogenicity of non-genotoxic chemicals. *Mutat Res*. 1995;328(2):127-49. PubMed PMID: 7739598.
237. Greenberg RS, Margolick J, Mattison DR, Spring S, Okey AB, Olive DL, Poland A, Rodricks JV, Rudenko L, Starr T. EPA ASSESSMENT NOT JUSTIFIED. *Environmental Science & Technology*. 1995;29(1):A31-A2. PubMed PMID: WOS:A1995PZ72300021.
238. Zucconi SL, Carson CA, Mattison DR, National Center for Health Statistics (U.S.). Monitoring and prioritization of CDC's consensus set of health status indicators by state health departments in the United States. Hyattsville, MD: National Center for Health Statistics; 1994. p. 445-9. p.
239. Takihi N, Rosenkranz HS, Klopman G, Mattison DR. Structural determinants of developmental toxicity. *Risk Anal*. 1994;14(4):649-57. Epub 1994/08/01. PubMed PMID: 7972965.
240. Silvaggio T, Mattison DR. Setting occupational health standards: toxicokinetic differences among and between men and women. *J Occup Med*. 1994;36(8):849-54. Epub 1994/08/01. PubMed PMID: 7807264.
241. Sharma R, Synkewecz C, Raggio T, Mattison DR. Intermediate variables as determinants of adverse pregnancy outcome in high-risk inner-city populations. *J Natl Med Assoc*. 1994;86(11):857-60. Epub 1994/11/01. PubMed PMID: 7807574; PMCID: PMC2607623.

242. Olshan AF, Mattison DR, Zwanenburg TSB. CYCLOSPORINE-A - REVIEW OF GENOTOXICITY AND POTENTIAL FOR ADVERSE HUMAN REPRODUCTIVE AND DEVELOPMENTAL EFFECTS - REPORT OF A WORKING GROUP ON THE GENOTOXICITY OF CYCLOSPORINE-A, AUGUST 18, 1993. *Mutation Research*. 1994;317(2):163-73. doi: 10.1016/0165-1110(94)90023-x. PubMed PMID: WOS:A1994ND53200005.
243. Olshan AF, Mattison DR, Zwanenburg TS. International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosporine A, August 18, 1993. *Mutat Res*. 1994;317(2):163-73. doi: 10.1016/0165-1110(94)90023-X. PubMed PMID: 7511794.
244. Olshan AF, Mattison DR. Male-mediated developmental toxicity. New York: Plenum Press; 1994. xii, 406 p. p.
245. Mattison DR, Sandler JD. Summary of the workshop on issues in risk assessment: quantitative methods for developmental toxicology. *Risk Anal*. 1994;14(4):595-604. PubMed PMID: 7972960.
246. Mattison DR. QUANTITATIVE RISK ASSESSMENT FOR PATERNALLY-MEDIATED DEVELOPMENTAL TOXICITY. Olshan AF, Mattison DR, editors1994. 261-84 p.
247. Mattison DR. Quantitative Risk Assessment for Paternally-Mediated Developmental Toxicity. Male-Mediated Developmental Toxicity1994. p. 261-84.
248. Green GM, Gordis L, Bingham E, Eschenbacher W, Gorman DW, Marcus M, Riley LW, Schaumburg HH, Singer MT, Spengler JD, Sutula TP, Taylor RE, Bascom R, Berg SW, Blanck RR, Bolton HT, Cortiveau J, Daxon EG, Eitzen EM, Evenson ET, Fagan JG, Feldman EL, Friedman GK, Friedman MJ, Fry SA, Fukuda K, Hagar B, Heller J, Hyams C, Irely NS, Johnson DL, Kang HK, Magill AJ, Marlowe DH, Mattison DR, Miller CS, Mohr SN, Murphy FM, Odonnell FL, Pillemer SR, Ross D, Roswell RH, Shayevitz M, Sidell FR, Straus SE, Tarver RS, Terr AI, Wade JV, Fox MA, Robertson S, Wolfe K, Zuspann B, Gerrity T, Beach PEM, Camp T, Custis DL, Etzel RA, Ferguson JH, Griesemer R, Hall WH, Harlan WR, Hickman JG, Kehrl H, Rauch T, Sphar RL, Thacker S, Venegas TN. THE PERSIAN-GULF EXPERIENCE AND HEALTH. *Jama-Journal of the American Medical Association*. 1994;272(5):391-6. doi: 10.1001/jama.1994.03520050071033. PubMed PMID: WOS:A1994NY90300033.
249. Bradfield CA, Gallo MA, Gasiewicz TA, Greenberg RS, Greenlee WF, Margolick J, Mattison DR, Munson P, Neal RA, Okey AB, et al. EPA dioxin reassessment. *Science*. 1994;266(5191):1628-9. Epub 1994/12/09. PubMed PMID: 7992038.
250. Silvaggio T, Mattison DR. ASSESSING REPRODUCTIVE RISKS WITH BIOLOGICAL MARKERS. Travis CC, editor1993. 137-58 p.
251. Mattison DR. Sites of female reproductive vulnerability: implications for testing and risk assessment. *Reprod Toxicol*. 1993;7 Suppl 1:53-62. Epub 1993/01/01. PubMed PMID: 8400641.
252. Marcus M, Silbergeld E, Mattison D. A reproductive hazards research agenda for the 1990s. Research Needs Working Group. *Environ Health Perspect*. 1993;101 Suppl 2(SUPPL. 2):175-80. PubMed PMID: 8243388; PMCID: PMC1519937.
253. Branstool E, Simon GC, Leahy P, Stenholm CW, Avery DT, Medley TL, Beachy RN, Mattison DR, Goldberg R, Caulder JD, Witt SC, Loew FM, Fox MW, Krinsky S, Vidaver A, Taylor SL, Anderson WT, Barnum A, Unger M. Food biotechnology: A new paradigm for food, the farm, and the public. *Bio/Technology*. 1993;11(13):1584-9.
254. Weitzman GA, Miller MM, London SN, Mattison DR. Morphometric assessment of the murine ovarian toxicity of 7,12-dimethylbenz(a)anthracene. *Reprod Toxicol*. 1992;6(2):137-41. Epub 1992/01/01. doi: 0890-6238(92)90115-A [pii]. PubMed PMID: 1591471.
255. Plowchalk DR, Meadows MJ, Mattison DR. Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 2. Effects on uterine structure and function. *Reprod Toxicol*. 1992;6(5):423-9. Epub 1992/01/01. PubMed PMID: 1463922.

256. Plowchalk DR, Mattison DR. Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 1. Effects on ovarian structure and function. *Reprod Toxicol.* 1992;6(5):411-21. PubMed PMID: 1463921.
257. Miller MM, Plowchalk DR, Weitzman GA, London SN, Mattison DR. The effect of benzo(a)pyrene on murine ovarian and corpora lutea volumes. *Am J Obstet Gynecol.* 1992;166(5):1535-41. Epub 1992/05/01. doi: 0002-9378(92)91630-S [pii]. PubMed PMID: 1595809.
258. Mattison DR, Wohlleb J, To T, Lamb Y, Faitak S, Brewster MA, Walls RC, Selevan SG. Pesticide concentrations in Arkansas breast milk. *J Ark Med Soc.* 1992;88(11):553-7. Epub 1992/04/01. PubMed PMID: 1644709.
259. Mattison DR. Protecting reproductive and developmental health under Proposition 65--public health approaches to knowledge, imperfect knowledge, and the absence of knowledge. *Reprod Toxicol.* 1992;6(1):1-7. Epub 1992/01/01. doi: 0890-6238(92)90016-M [pii]. PubMed PMID: 1562795.
260. Davis DL, Friedler G, Mattison D, Morris R. Male-mediated teratogenesis and other reproductive effects: biologic and epidemiologic findings and a plea for clinical research. *Reprod Toxicol.* 1992;6(4):289-92. PubMed PMID: 1521000.
261. Bertin JE, Ashford NA, Bellinger D, Landrigan PJ, Legator MS, Mattison DR, McBeath WH, Rosen JF, Stellman JM. The goal: safety and equality. *Am J Ind Med.* 1992;21(4):463-5. PubMed PMID: 1580251.
262. Angtuaco TL, Shah HR, Mattison DR, Quirk JG, Jr. MR imaging in high-risk obstetric patients: a valuable complement to US. *Radiographics.* 1992;12(1):91-109; discussion 10. Epub 1992/01/11. doi: 10.1148/radiographics.12.1.1734485. PubMed PMID: 1734485.
263. Smith BJ, Plowchalk DR, Sipes IG, Mattison DR. Comparison of random and serial sections in assessment of ovarian toxicity. *Reprod Toxicol.* 1991;5(4):379-83. Epub 1991/01/01. doi: 0890-6238(91)90097-Y [pii]. PubMed PMID: 1806143.
264. Smith BJ, Mattison DR, Sipes IG. Hepatic bioactivation of 4-vinylcyclohexene to ovotoxic epoxides. *Adv Exp Med Biol.* 1991;283:465-70. Epub 1991/01/01. PubMed PMID: 2069018.
265. Plowchalk DR, Mattison DR. Phosphoramidate mustard is responsible for the ovarian toxicity of cyclophosphamide. *Toxicol Appl Pharmacol.* 1991;107(3):472-81. Epub 1991/03/01. PubMed PMID: 2000634.
266. Mattison DR, Working PK, Blazak WF, Hughes Jr. CL, Killinger JM, Olive DL, Rao KS, Hanson JW, Kochhar DM. In reply. *Reproductive Toxicology.* 1991;5(3):175-8.
267. Mattison DR, Working PK, Blazak WF, Hughes CL, Killinger JM, Olive DL, Rao KS, Hanson JW, Kochhar DM. WHEN SCIENTISTS BECOME POLICY MAKERS - SHAPING HAZARD IDENTIFICATION UNDER PROPOSITION-65 - REPLY. *Reproductive Toxicology.* 1991;5(3):175-8. doi: 10.1016/0890-6238(91)90049-I. PubMed PMID: WOS:A1991FM05300002.
268. Mattison DR, Blann E, Malek A. Physiological alterations during pregnancy: impact on toxicokinetics. *Fundam Appl Toxicol.* 1991;16(2):215-8. Epub 1991/02/01. PubMed PMID: 2055350.
269. Mattison DR. An overview on biological markers in reproductive and developmental toxicology: concepts, definitions and use in risk assessment. *Biomed Environ Sci.* 1991;4(1-2):8-34. Epub 1991/06/01. PubMed PMID: 1910604.
270. Crall HD, Mattison DR. Oxytocin pharmacodynamics: effect of long infusions on uterine activity. *Gynecol Obstet Invest.* 1991;31(1):17-22. PubMed PMID: 2010111.
271. Case BW, Mattison DR. RISK ASSESSMENT IN PATHOLOGY EDUCATION. Craighead JE, editor 1991. 77-83 p.
272. Smith BJ, Mattison DR, Sipes IG. The role of epoxidation in 4-vinylcyclohexene-induced ovarian toxicity. *Toxicol Appl Pharmacol.* 1990;105(3):372-81. Epub 1990/09/15. PubMed PMID: 2237912.
273. Mattison DR, Working PK, Blazak WF, Hughes CL, Jr., Killinger JM, Olive DL, Rao KS. Criteria for identifying and listing substances known to cause reproductive toxicity under California's Proposition 65. *Reprod Toxicol.* 1990;4(3):163-75. doi: 10.1016/0890-6238(90)90055-Z. PubMed PMID: 2136034.

274. Mattison DR, Bogumil RJ, Chapin R, Hatch M, Hendrickx A, Jarrell J, LaBarbera AL, Schrader SM, Selevan S. Reproductive effects of pesticides. *Advances in Modern Environmental Toxicology*. 1990;18:297-389.
275. Mattison DR. Exclusion of fertile women from the workplace: bad medicine, worse law. *J Ark Med Soc*. 1990;86(12):491-2. Epub 1990/05/01. PubMed PMID: 2140350.
276. Mattison DR. Transdermal drug absorption during pregnancy. *Clin Obstet Gynecol*. 1990;33(4):718-27. Epub 1990/12/01. PubMed PMID: 2289338.
277. Mattison D, Plowchalk D, Meadows M, Al-Juburi A, Gandy J, Malek A. Reproductive toxicity: male and female reproductive systems as targets for chemical injury. *The Medical Clinics of North America*. 1990;74(2):391-411. PubMed PMID: WOS:A1990CV45500012.
278. Malek A, Miller RK, Mattison DR, Bryant R, Panigel M, Neth L. ENERGY-PRODUCTION BY THE DUALY PERFUSED TERM HUMAN PLACENTA INVITRO - P-31 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY AT 2.0 AND 4.7 TESLA. Cedard L, Alsat E, Challier JC, Chaouat G, Malassine A, editors1990. 199-200 p.
279. Malek A, Meadows MJ, Miller FC, Mattison DR. CONTINUOUS O-2(P) MONITORING DURING DUAL PERFUSION OF THE TERM HUMAN PLACENTA. Cedard L, Alsat E, Challier JC, Chaouat G, Malassine A, editors1990. 203-4 p.
280. Malek A, Meadows MJ, Miller FC, Blann E, Mattison DR. FETAL TO MATERNAL TRANSPORT OF OXYTOCIN ACROSS THE DUAL PERFUSED HUMAN PLACENTA. Cedard L, Alsat E, Challier JC, Chaouat G, Malassine A, editors1990. 201-2 p.
281. Jelovsek FR, Mattison DR, Young JF. Eliciting principles of hazard identification from experts. *Teratology*. 1990;42(5):521-33. Epub 1990/11/01. doi: 10.1002/tera.1420420509. PubMed PMID: 2278027.
282. Jelovsek FR, Mattison DR. Application of artificial intelligence to clinical practice. *Computers and perinatal medicine: proceedings of the 2nd World Symposium "Computers in the Care of the Mother, Fetus and Newborn" ICS907*. 1990:47-53. PubMed PMID: WOS:A1990BR43S00005.
283. Sheehan DM, Young JF, Slikker W, Jr., Gaylor DW, Mattison DR. Workshop on risk assessment in reproductive and developmental toxicology: addressing the assumptions and identifying the research needs. *Regul Toxicol Pharmacol*. 1989;10(2):110-22. Epub 1989/10/01. doi: 0273-2300(89)90018-4 [pii]. PubMed PMID: 2682812.
284. Plowchalk DR, Mattison DR. OVARIAN MORPHOMETRIC CHANGES FOLLOWING CYCLOPHOSPHAMIDE TREATMENT. Hirshfield AN, editor1989. 427-31 p.
285. National Research Council (U.S.). Subcommittee on Reproductive and Neurodevelopmental Toxicology. *Biologic markers in reproductive toxicology*. Washington, D.C.: National Academy Press; 1989. xxi, 395 p. p.
286. Mattison DR, Thomford PJ. The mechanisms of action of reproductive toxicants. *Toxicol Pathol*. 1989;17(2):364-76. PubMed PMID: 2675287.
287. Mattison DR, Singh H, Takizawa K, Thomford PJ. Ovarian toxicity of benzo(a)pyrene and metabolites in mice. *Reprod Toxicol*. 1989;3(2):115-25. PubMed PMID: 2485204.
288. Mattison DR, Plowchalk DR, Meadows MJ, Miller MM, Malek A, London S. The effect of smoking on oogenesis, fertilization, and implantation. *Seminars in Reproductive Endocrinology*. 1989;7(4):291-304.
289. Mattison DR, Plowchalk DR, Meadows MJ. FEMALE REPRODUCTIVE TOXICOLOGY. Velasco M, Israel A, Remero E, Silva H, editors1989. 151-7 p.
290. Mattison DR, Plowchalk DR, Meadows MJ. MECHANISMS OF ACTION OF REPRODUCTIVE TOXICANTS. Velasco M, Israel A, Remero E, Silva H, editors1989. 141-5 p.

291. Mattison DR, Plowchalk DR, Meadows MJ. Female reproductive toxicology. Recent advances in pharmacology and therapeutics: proceedings of the XII Latin-American Congress of Pharmacology and the III Inter-American Congress of Clinical Pharmacology and Therapeutics ICS839. 1989;151-7.
292. Mattison DR, Hanson JW, Kochhar DM, Rao KS. Criteria for identifying and listing substances known to cause developmental toxicity under California's Proposition 65. *Reprod Toxicol.* 1989;3(1):3-12. Epub 1989/01/01. PubMed PMID: 2520504.
293. Mattison DR, Angtuaco T, Miller FC, Quirk JG. Magnetic resonance imaging in maternal and fetal medicine. *J Perinatol.* 1989;9(4):411-9. Epub 1989/12/01. PubMed PMID: 2687441.
294. Jelovsek FR, Mattison DR, Chen JJ. Prediction of risk for human developmental toxicity: how important are animal studies for hazard identification? *Obstet Gynecol.* 1989;74(4):624-36. Epub 1989/10/01. doi: 0029-7844(89)90105-1 [pii]. PubMed PMID: 2797639.
295. Heindel JJ, Thomford PJ, Mattison DR. HISTOLOGICAL ASSESSMENT OF OVARIAN FOLLICLE NUMBER IN MICE AS A SCREEN FOR OVARIAN TOXICITY. Hirshfield AN, editor 1989. 421-6 p.
296. Bengtsson M, Mattison DR. Gonadotropin-dependent metabolism of 7,12-dimethylbenz(a)anthracene in the ovary of rhesus monkey. *Biochem Pharmacol.* 1989;38(11):1869-72. Epub 1989/06/01. doi: 0006-2952(89)90425-5 [pii]. PubMed PMID: 2500126.
297. Swartz WJ, Mattison DR. Galactose inhibition of ovulation in mice. *Fertil Steril.* 1988;49(3):522-6. Epub 1988/03/01. PubMed PMID: 3342905.
298. Smith MA, Thomford PJ, Mattison DR, Slikker W, Jr. Transport and metabolism of dexamethasone in the dually perfused human placenta. *Reprod Toxicol.* 1988;2(1):37-43. PubMed PMID: 2980400.
299. Slikker W, Thomford PJ, Plowchalk DR, Mattison DR. COMPARISON OF THE CAPACITY OF TERM MONKEY AND HUMAN INVITRO DUALY PERFUSED PLACENTA TO TRANSFER AND METABOLIZE ESTRADIOL. *Teratology.* 1988;37(5):494-. PubMed PMID: WOS:A1988N191100164.
300. Mattison DR, Thomford PJ, Jelovsek FR. Disposition of oocytes and age at menopause. *N Engl J Med.* 1988;318(10):644. Epub 1988/03/10. doi: 10.1056/NEJM198803103181019. PubMed PMID: 3344014.
301. Mattison DR, Plowchalk DR, Meadows MJ, editors. Female reproductive toxicology. The XII Latin-American Congress of Pharmacology and the III Inter-American Congress of Clinical Pharmacology and Therapeutics; 1988 1989: Elsevier Science Publishers B.V.
302. Mattison DR, Plowchalk DR, Meadows MJ, editors. Mechanisms of action of reproductive toxicants. The XII Latin-American Congress of Pharmacology and the III Inter-American Congress of Clinical Pharmacology and Therapeutics; 1988 1989: Elsevier Science Publishers B.V.
303. Mattison DR, Kay HH, Miller RK, Angtuaco T. Magnetic resonance imaging: a noninvasive tool for fetal and placental physiology. *Biol Reprod.* 1988;38(1):39-49. Epub 1988/02/01. PubMed PMID: 3284598.
304. Mattison DR, Brewer DW. Computer modeling of human fertility: the impact of reproductive heterogeneity on measures of fertility. *Reprod Toxicol.* 1988;2(3-4):253-71. Epub 1988/01/01. PubMed PMID: 2980356.
305. Mattison DR, Angtuaco T. Magnetic resonance imaging in prenatal diagnosis. *Clin Obstet Gynecol.* 1988;31(2):353-89. Epub 1988/06/01. PubMed PMID: 3042221.
306. Jarrell J, Mattison DR, McMahon A, Younglai EV. An evaluation of the serum FSH as a biomarker for ovarian toxicity in the rat. *Reprod Toxicol.* 1988;2(2):111-5. Epub 1988/01/01. PubMed PMID: 2980404.
307. Harris MB, Angtuaco T, Frazier CN, Mattison DR. Diagnosis of a viable abdominal pregnancy by magnetic resonance imaging. *Am J Obstet Gynecol.* 1988;159(1):150-1. Epub 1988/07/01. doi: 0002-9378(88)90511-X [pii]. PubMed PMID: 3394735.

308. Gaylor DW, Sheehan DM, Young JF, Mattison DR. The threshold dose question in teratogenesis. *Teratology*. 1988;38(4):389-91. Epub 1988/10/01. doi: 10.1002/tera.1420380410. PubMed PMID: 3238595.
309. Thomford PJ, Jelovsek FR, Mattison DR. Effect of oocyte number and rate of atresia on the age of menopause. *Reprod Toxicol*. 1987;1(1):41-51. Epub 1987/01/01. PubMed PMID: 2980363.
310. Silbergeld EK, Mattison DR. Experimental and clinical studies on the reproductive toxicology of 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Am J Ind Med*. 1987;11(2):131-44. Epub 1987/01/01. PubMed PMID: 3548340.
311. Plowchalk DR, Jordan JP, Thomford PJ, Mattison DR. Effects of manganese (Mn⁺⁺) and iron (Fe⁺⁺⁺) on magnetic resonance imaging (MRI) characteristics of human placenta and amniotic fluid. *Physiol Chem Phys Med NMR*. 1987;19(1):35-41. Epub 1987/01/01. PubMed PMID: 3615643.
312. Miller RK, Mattison DR, Panigel M, Ceckler T, Bryant R, Thomford P. Kinetic assessment of manganese using magnetic resonance imaging in the dually perfused human placenta in vitro. *Environ Health Perspect*. 1987;74:81-91. Epub 1987/10/01. PubMed PMID: 3691434; PMCID: PMC1474511.
313. Mattison DR, Thomford PJ. The effect of smoking on reproductive ability and reproductive lifespan. *Smoking and Reproductive Health*. Littleton, Massachusetts, : PSG Publishing Company,; 1987. p. p. 47-54.
314. Mattison DR, Jelovsek FR. Pharmacokinetics and expert systems as aids for risk assessment in reproductive toxicology. *Environ Health Perspect*. 1987;76:107-19. Epub 1987/12/01. PubMed PMID: 3447888; PMCID: PMC1474465.
315. Kay HH, Knop RC, Mattison DR. Magnetic resonance imaging of monkey placenta with manganese enhancement. *Am J Obstet Gynecol*. 1987;157(1):185-9. Epub 1987/07/01. PubMed PMID: 3605252.
316. Goldstein B, Gibson J, Henderson R, Hobbie J, Landrigan P, Mattison D, Perera F, Pfitzer E, Silbergeld E, Wogan G. Biological markers in environmental health research. *Environmental Health Perspectives*. 1987;74:3-9.
317. Ewing LL, Mattison DR. Biological markers of male reproductive toxicology. *Environ Health Perspect*. 1987;74:11-3. Epub 1987/10/01. PubMed PMID: 3691425; PMCID: PMC1474517.
318. Bengtsson M, Dong Y, Mattison DR, Rydstrom J. Mechanisms of regulation of rat ovarian 7,12-dimethylbenz[a]anthracene hydroxylase. *Chem Biol Interact*. 1987;63(1):15-27. Epub 1987/01/01. doi: 0009-2797(87)90101-3 [pii]. PubMed PMID: 3115604.
319. Thomford PJ, Mattison DR. The effect of cigarette smoking on female reproduction. *J Ark Med Soc*. 1986;82(12):597-604. Epub 1986/05/01. PubMed PMID: 2940228.
320. Quirk JG, Hill D, Keppen L, Char F, Brewster M, Butler B, Hawks F, Hale M, Mattison DR. TERATOLOGY INFORMATION AND COUNSELING IN A RURAL STATE. *Teratology*. 1986;33(3):C52-C. PubMed PMID: WOS:A1986C749400103.
321. Pfeiffer D, Mattison DR, Nikolarakis KE. OVARIAN FAILURE AFTER CHEMOTHERAPY DUE TO TOXIC EFFECTS ON THE OVARY AND HYPOTHALAMUS-PITUITARY AXIS. *Acta Endocrinologica*. 1986;111:7-. PubMed PMID: WOS:A1986C474000007.
322. Miller RK, Panigel M, Ceckler T, Mattison DR, Bryant R. Magnetic resonance imaging (MRI) of the circulation and the heterogeneous distribution of manganese chloride compared with the uptake of ⁵⁴Mn in the dually-perfused isolated human placental lobule. *Placenta*. 1986;7(5):446-7. doi: 10.1016/s0143-4004(86)80038-8. PubMed PMID: WOS:A1986E399900013.
323. Mattison DR, Miller RK, Panigel M, Bryant R, Marill K. MAGNETIC-RESONANCE-IMAGING (MRI) IN THE HUMAN-PLACENTA - THE PHARMACOKINETICS OF MANGANESE (MN). *Teratology*. 1986;33(3):C32-C. PubMed PMID: WOS:A1986C749400038.
324. Cloud JA, Taylor D, Smerud M, Angtuaco T, Mattison DR. Prenatal diagnosis of omphalocele. *J Ark Med Soc*. 1986;82(9):403-6. Epub 1986/02/01. PubMed PMID: 2937766.

325. Swartz WJ, Mattison DR. Benzo(a)pyrene inhibits ovulation in C57BL/6N mice. *Anat Rec.* 1985;212(3):268-76. Epub 1985/07/01. doi: 10.1002/ar.1092120308. PubMed PMID: 4061880.
326. Shiromizu K, Mattison DR. Murine oocyte destruction following intraovarian treatment with 3-methylcholanthrene or 7,12-dimethylbenz(a)anthracene: protection by alpha-naphthoflavone. *Teratog Carcinog Mutagen.* 1985;5(6):463-72. Epub 1985/01/01. PubMed PMID: 2874631.
327. Angtuaco T, Mattison D, Thomford P, Jordan J. Effect of manganese on human placental spin-lattice (T1) and spin-spin (T2) relaxation times. *Physiological chemistry and physics and medical NMR.* 1985;18(1):41-8. PubMed PMID: WOS:A1986E183300006.
328. Takizawa K, Yagi H, Jerina DM, Mattison DR. Murine strain differences in ovotoxicity following intraovarian injection with benzo(a)pyrene, (+)-(7R,8S)-oxide, (-)-(7R,8R)-dihydrodiol, or (+)-(7R,8S)-diol-(9S,10R)-epoxide-2. *Cancer Res.* 1984;44(6):2571-6. Epub 1984/06/01. PubMed PMID: 6327019.
329. Swartz WJ, Silbergeld E, Malley K, Mattison DR. THE EFFECTS OF BENZO(A)PYRENE ON MURINE OVARIAN-FUNCTION AND FERTILITY. *Anatomical Record.* 1984;208(3):A177-A8. PubMed PMID: WOS:A1984SH33600529.
330. Shiromizu K, Thorgeirsson SS, Mattison DR. Effect of cyclophosphamide on oocyte and follicle number in Sprague-Dawley rats, C57BL/6N and DBA/2N mice. *Pediatr Pharmacol (New York).* 1984;4(4):213-21. Epub 1984/01/01. PubMed PMID: 6522129.
331. Shiromizu K, Mattison DR. The effect of intraovarian injection of benzo(a)pyrene on primordial oocyte number and ovarian aryl hydrocarbon [benzo(a)pyrene] hydroxylase activity. *Toxicol Appl Pharmacol.* 1984;76(1):18-25. Epub 1984/10/01. PubMed PMID: 6484988.
332. Mattison DR, Evans MI, Schwimmer WB, White BJ, Jensen B, Schulman JD. Familial premature ovarian failure. *Am J Hum Genet.* 1984;36(6):1341-8. PubMed PMID: 6517055; PMCID: PMC1684657.
333. East IJ, Mattison DR, Dean J. Monoclonal antibodies to the major protein of the murine zona pellucida: effects on fertilization and early development. *Dev Biol.* 1984;104(1):49-56. Epub 1984/07/01. doi: 0012-1606(84)90035-6 [pii]. PubMed PMID: 6376213.
334. Chen YT, Mattison DR, Bercu BB, Schulman JD. Resistance of the male gonad to a high galactose diet. *Pediatr Res.* 1984;18(4):345-8. Epub 1984/04/01. PubMed PMID: 6718090.
335. Takizawa K, Yagi H, Jerina DM, Mattison DR. INTRAOVARIAN INJECTION TECHNIQUE, A NEW ASSAY IN THE EVALUATION OF MUTAGENICITY AND CARCINOGENICITY. *Proceedings of the American Association for Cancer Research.* 1983;24(MAR):53-. PubMed PMID: WOS:A1983RM38200206.
336. Takizawa K, Mattison DR. Female reproduction. *Am J Ind Med.* 1983;4(1-2):17-30. Epub 1983/01/01. PubMed PMID: 6340476.
337. Mattison DR, Shiromizu K, Pendergrass JA, Thorgeirsson SS. Ontogeny of ovarian glutathione and sensitivity to primordial oocyte destruction by cyclophosphamide. *Pediatr Pharmacol (New York).* 1983;3(1):49-55. Epub 1983/01/01. PubMed PMID: 6646878.
338. Mattison DR, Shiromizu K, Nightingale MS. Oocyte destruction by polycyclic aromatic hydrocarbons. *Am J Ind Med.* 1983;4(1-2):191-202. Epub 1983/01/01. PubMed PMID: 6301272.
339. Mattison DR, Nightingale MS, Shiromizu K. Effects of toxic substances on female reproduction. *Environ Health Perspect.* 1983;48:43-52. Epub 1983/02/01. PubMed PMID: 6825634; PMCID: PMC1569060.
340. Mattison DR, King JC. Development of a nonhuman primate model for fetoscopy. *J Med Primatol.* 1983;12(6):319-30. Epub 1983/01/01. PubMed PMID: 6209400.
341. Mattison DR. Reproductive toxicology. *American Journal of Industrial Medicine.* 1983;4(1-2):1-2. PubMed PMID: 695863044; 1983146825.
342. Mattison DR. The mechanisms of action of reproductive toxins. *Am J Ind Med.* 1983;4(1-2):65-79. Epub 1983/01/01. PubMed PMID: 6340485.
343. Mattison DR. Preface: Reproductive toxicology. *American Journal of Industrial Medicine.* 1983;4(1):1-2. doi: 10.1002/ajim.4700040102. PubMed PMID: WOS:A1983QD84100001.

344. Kuroda D, Henry C, Felton J, Nightingale M, Mattison D. EFFECT OF CIGARETTE-SMOKE INHALATION, INTRATRACHIAL, OR INTRAPERITONEAL BENZO(A)PYRENE TREATMENT ON OOCYTE NUMBER IN C57BL, C3H, AND (C57BLXC3H) F1-MICE. *Journal of the American College of Toxicology*. 1983;2(2):246-. PubMed PMID: WOS:A1983QT74300042.
345. Shiromizu K, Takizawa K, Mattison DR. OOCYTE DESTRUCTION BY INTRA-OVARIAN INJECTION OF POLYCYCLIC AROMATIC-HYDROCARBONS. *Journal of the American College of Toxicology*. 1982;1(3):123-. PubMed PMID: WOS:A1982PQ19100053.
346. Mattison DR, Nightingale MS. Oocyte destruction by polycyclic aromatic hydrocarbons is not linked to the inducibility of ovarian aryl hydrocarbon (benzo(a)pyrene) hydroxylase activity in (DBA/2N X C57BL/6N) F1 X DBA/2N backcross mice. *Pediatr Pharmacol (New York)*. 1982;2(1):11-21. doi: 10.1002/ajim.4700040117. PubMed PMID: 7110752.
347. Mattison DR. The effects of smoking on fertility from gametogenesis to implantation. *Environ Res*. 1982;28(2):410-33. Epub 1982/08/01. PubMed PMID: 6749489.
348. Lazarte RA, Kuroda D, Mattison DR. CIMETIDINE DOES NOT INHIBIT ZOAZOLAMINE METABOLISM IN CONTROL OR 3-METHYLCHOLANTHRENE TREATED DBA 2N OR C57BL 6N MICE. *Clinical Research*. 1982;30(2):A633-A. PubMed PMID: WOS:A1982NJ70702805.
349. King JC, Mattison DR. Fetoscopy: a tool for fetal diagnosis, therapy, and research. *Semin Perinatol*. 1982;6(2):195-204. Epub 1982/04/01. PubMed PMID: 7100936.
350. Soyka LF, Mattison DR, Kramer RJ, Nebert DW. CONTENT AND ORGANIZATION OF SPERMATOZOAN DNA. *Pediatric Research*. 1981;15(4):502-. doi: 10.1203/00006450-198104001-00384. PubMed PMID: WOS:A1981LG15500375.
351. Orgebin-Crist MC, Greep RO, Jaffe RB, Sadler WA, Mattison DR, Sherins RJ. Fertility and infertility. Washington, D.C., Educational Resources Information Center, 1981. 46 p. p.
352. Mattison DR, Nightingale MR. OOCYTE DESTRUCTION BY BENZO(A)PYRENE (BP), 3-HYDROXY-BP (3-HOBP), 4,5-DIHYDROEPOXY-BP (4,5-EBP), CIS AND TRANS 4,5-DIHYDRODIOL-BP (4,5-DHDO(CIS), 4,5-DHDO(TRANS)). *Proceedings of the American Association for Cancer Research*. 1981;22(MAR):80-. PubMed PMID: WOS:A1981LH80000316.
353. Mattison DR, Chang L, Thorgeirsson SS, Shiromizu K. The effects of cyclophosphamide, azathioprine, and 6-mercaptopurine on oocyte and follicle number in C57BL/6N mice. *Res Commun Chem Pathol Pharmacol*. 1981;31(1):155-61. Epub 1981/01/01. PubMed PMID: 7196066.
354. Mattison D, Nightingale M. Oocyte destruction by polycyclic aromatic hydrocarbons is not linked to the inducibility of ovarian aryl hydrocarbon (benzo (a) pyrene) hydroxylase activity in (DBA/2N X C57BL/6N) F1 X DBA/2N backcross mice. *Pediatric pharmacology (New York, NY)*. 1981;2(1):11-21. PubMed PMID: WOS:A1982ND53500002.
355. Chen YT, Mattison DR, Schulman JD. HYPOGONADISM AND GALACTOSEMIA. *New England Journal of Medicine*. 1981;305(8):464-. PubMed PMID: WOS:A1981MB62700019.
356. Chen YT, Mattison DR, Feigenbaum L, Fukui H, Schulman JD. Reduction in oocyte number following prenatal exposure to a diet high in galactose. *Science*. 1981;214(4525):1145-7. Epub 1981/12/04. PubMed PMID: 7302587.
357. Chen YT, Mattison D, Feigenbaum L, Fukui H, Schulman JD. REDUCTION IN OOCYTE NUMBER FOLLOWING PRENATAL EXPOSURE TO A HIGH GALACTOSE DIET. *Pediatric Research*. 1981;15(4):642-. doi: 10.1203/00006450-198104001-01224. PubMed PMID: WOS:A1981LG15501214.
358. Abdul-Karim RW. *Drugs during pregnancy : clinical perspectives*. Philadelphia: G.F. Stickley; 1981. vii, 152 p. p.
359. Mattison DR, Yeh SY. Hemoperitoneum from rupture of a uterine vein overlying a leiomyoma. *Am J Obstet Gynecol*. 1980;136(3):415-6. Epub 1980/02/01. doi: 0002-9378(80)90876-5 [pii]. PubMed PMID: 7352537.

360. Mattison DR, White NB, Nightingale MR. The effect of benzo(a)pyrene on fertility, primordial oocyte number, and ovarian response to pregnant mare's serum gonadotropin. *Pediatr Pharmacol (New York)*. 1980;1(2):143-51. Epub 1980/01/01. PubMed PMID: 6287394.
361. Mattison DR, Shiromizu K. PRIMORDIAL OOCYTE DESTRUCTION BY CYCLOPHOSPHAMIDE. *Proceedings of the American Association for Cancer Research*. 1980;21(MAR):270-. PubMed PMID: WOS:A1980JP67101067.
362. Mattison DR, Nightingale MR. THE BIOCHEMICAL AND GENETIC-CHARACTERISTICS OF MURINE OVARIAN ARYL-HYDROCARBON (BENZO ALPHA PYRENE) HYDROXYLASE-ACTIVITY AND ITS RELATIONSHIP TO PRIMORDIAL OOCYTE DESTRUCTION BY POLYCYCLIC AROMATIC-HYDROCARBONS. *Toxicology and Applied Pharmacology*. 1980;56(3):399-408. doi: 10.1016/0041-008x(80)90074-5. PubMed PMID: WOS:A1980KW72400013.
363. Mattison DR, Nightingale MR. The biochemical and genetic characteristics of murine ovarian aryl hydrocarbon (benzo[a])pyrene hydroxylase activity and its relationship to primordial oocyte destruction by polycyclic aromatic hydrocarbons. *Toxicol Appl Pharmacol*. 1980;56(3):399-408. Epub 1980/12/01. PubMed PMID: 7222024.
364. Mattison DR. Morphology of oocyte and follicle destruction by polycyclic aromatic hydrocarbons in mice. *Toxicol Appl Pharmacol*. 1980;53(2):249-59. Epub 1980/04/01. doi: 0041-008X(80)90424-X [pii]. PubMed PMID: 6771884.
365. Thorgeirsson SS, Levitt DS, Everson RB, Schut HAJ, Staiano N, Mattison DR. RELATIVE MUTAGENICITY AND OVO-TOXICITY OF ANTI-TUMOR AGENTS. *Pharmacologist*. 1979;21(3):187-. PubMed PMID: WOS:A1979HD04600227.
366. Menard RH, West DM, Mattison DR, Gelboin HV. ARYL-HYDROCARBON HYDROXYLASE-ACTIVITY IN THE ADRENAL-GLAND OF THE RAT AND MOUSE - EFFECT OF 3-METHYLCHOLANTHRENE TREATMENT. *Federation Proceedings*. 1979;38(3):527-. PubMed PMID: WOS:A1979GL65501581.
367. Mattison DR, West DM, Menard RH. Differences in benzo(a)pyrene metabolic profile in rat and mouse ovary. *Biochem Pharmacol*. 1979;28(13):2101-4. Epub 1979/07/01. doi: 0006-2952(79)90232-6 [pii]. PubMed PMID: 475853.
368. Mattison DR, Thorgeirsson SS. Ovarian aryl hydrocarbon hydroxylase activity and primordial oocyte toxicity of polycyclic aromatic hydrocarbons in mice. *Cancer Res*. 1979;39(9):3471-5. Epub 1979/09/01. PubMed PMID: 113091.
369. Mattison DR. Difference in sensitivity of rat and mouse primordial oocytes to destruction by polycyclic aromatic hydrocarbons. *Chem Biol Interact*. 1979;28(1):133-7. Epub 1979/01/01. doi: 0009-2797(79)90120-0 [pii]. PubMed PMID: 115601.
370. Mattison D, White N, Nightingale M. The effect of benzo (a) pyrene on fertility, primordial oocyte number, and ovarian response to pregnant mare's serum gonadotropin. *Pediatric pharmacology (New York, NY)*. 1979;1(2):143-51. PubMed PMID: WOS:A1980LB66400007.
371. Gulyas BJ, Mattison DR. Degeneration of mouse oocytes in response to polycyclic aromatic hydrocarbons. *Anat Rec*. 1979;193(4):863-82. Epub 1979/04/01. doi: 10.1002/ar.1091930409. PubMed PMID: 426311.
372. Mattison DR, Thorgeirsson SS. GONADAL ARYL-HYDROCARBON HYDROXYLASE IN RATS AND MICE. *Cancer Research*. 1978;38(5):1368-73. PubMed PMID: WOS:A1978EX66300030.
373. Mattison DR, Thorgeirsson SS. Gonadal aryl hydrocarbon hydroxylase in rats and mice. *Cancer Res*. 1978;38(5):1368-73. Epub 1978/05/01. PubMed PMID: 25134.
374. Mattison DR, Thorgeirsson SS. Smoking and industrial pollution, and their effects on menopause and ovarian cancer. *Lancet*. 1978;1(8057):187-8. Epub 1978/01/28. PubMed PMID: 74610.
375. Mattison DR. EFFECT OF PRETREATMENT WITH ALPHA-NAPHTHOFLAVONE (ANF) AND NUCLEOPHILES ON 7,12-DIMETHYLBENZ(A)ANTHRACENE (DMBA) TOXICITY AND DEATH IN DBA-2N (D2)

- AND C57BL-6N (B6) MICE. Proceedings of the American Association for Cancer Research. 1978;19(MAR):45-. PubMed PMID: WOS:A1978EP04700177.
376. Gulyas BJ, Mattison DR. OOCYTE-ATRESIA INDUCED BY 3-METHYLCHOLANTHRENE IN MICE. Journal of Cell Biology. 1978;79(2):A175-A. PubMed PMID: WOS:A1978FV54600504.
377. Mattison DR, Thorgeirsson SS. STRAIN DIFFERENCES IN MOUSE OVARIAN ARYL-HYDROCARBON HYDROXYLASE AND OVOTOXICITY. Proceedings of the American Association for Cancer Research. 1977;18(MAR):18-. PubMed PMID: WOS:A1977DC08200069.
378. Mattison DR, Thorgeirsson SS. OVARIAN METABOLISM OF POLYCYCLIC AROMATIC-HYDROCARBONS AND ASSOCIATED OVO-TOXICITY IN MOUSE. Gynecologic Investigation. 1977;8(1-2):11-. PubMed PMID: WOS:A1977CX35100004.
379. Mattison DR, Thorgeirsson SS. Genetic differences in mouse ovarian metabolism of benzo [a]pyrene and oocyte toxicity. Biochem Pharmacol. 1977;26(9):909-12. Epub 1977/05/01. doi: 0006-2952(77)90414-2 [pii]. PubMed PMID: 861061.
380. Mattison DR, Thorgeirsson SS. INDUCTION OF OVARIAN ARYL-HYDROCARBON HYDROXYLASE AND N-ACETYLRYLAMINE N-HYDROXYLASE BY 3-METHYLCHOLANTHRENE AND ASSOCIATED INCREASES IN MUTAGENESIS. Federation Proceedings. 1976;35(3):409-. PubMed PMID: WOS:A1976BH49601124.
381. Mattison DR. Twinning. N Engl J Med. 1972;286(9):493-4. Epub 1972/03/02. PubMed PMID: 5061903.
382. Blanc WA, Mattison DR, Kane R, Chauthan P. L.S.D., intrauterine amputations, and amniotic-band syndrome. Lancet. 1971;2(7716):158-9. PubMed PMID: 4104480.
383. Mattison DR. Amniotic fluid osmolality. Obstet Gynecol. 1970;36(3):420-4. Epub 1970/09/01. PubMed PMID: 5456835.
384. Coffman RE, Lyle DL, Mattison DR. Small tunneling effect in the electron paramagnetic resonance spectrum of copper-(II)-calcium oxide at 1.2.degree.K. The Journal of Physical Chemistry. 1968;72(4):1392-4. doi: 10.1021/j100850a060. PubMed PMID: WOS:A1968A949300062.